A recombinant chimeric protein for selectins targeting

ABSTRACT

The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.

FIELD OF THE INVENTION

The present invention relates to the preparation of a novel Selectintargeting protein for diagnostic and therapeutic uses.

STATE OF THE ART

P-selectin glycoprotein ligand-1 (PSGL-1) is a leukocyte adhesionmolecule that mediates cell tethering and rolling on activatedendothelium cells under physiological blood flow. This activity is animportant initial step in leukocyte extravasation. PSGL-1 was initiallyidentified as a ligand for P-selectin, and subsequent work has revealedthat PSGL-1 is also a ligand for E-selectin and L-selectin (see, e.g.,U.S. Pat. No. 6,277,975).

Two members of the selectin family have particular relevance in thecontext of molecular imaging: P-selectin and E-selectin. Up-regulationor expression of P- and E-selectin on the vascular endothelium is knownto occur under conditions of inflammation, while the presence ofendothelial selectins under resting conditions is generally low to nil.Disease states in which selectins are useful molecular imaging targetsinclude post-ischemic injury, acute coronary syndrome, arthritis,inflammatory bowel disease including ileitis and colitis,atherosclerosis, myocarditis, thrombosis and multiple sclerosis.However, selectin molecular imaging may be useful to delineate andidentify tissues in which selectin expression occurs under normalconditions, such as the skin microvasculature.

Up-regulation of P-selectin (also called CD62P) is known to occur veryrapidly (within minutes), making P-selectin a potential marker of earlystages of inflammatory disease. P-selectin is also found on the surfaceof activated platelets, making it a marker of thrombosis. E-selectin(CD62E) is also expressed on inflamed vasculature, although generallylater in the inflammatory response than P-selectin. E-selectin is thus auseful marker of inflammation at later stages of the disease.

Among selectins' ligands, PSGL-1 plays an important role in therecruitment of white blood cells into inflamed tissues. White bloodcells normally do not interact with the endothelium of blood vessels.However, inflammation causes the expression of cell adhesion molecules(CAM) such as P-selectin on the surface of the blood vessel wall. Whiteblood cells present in flowing blood can interact with CAM. The firststep in this interaction process is carried out by PSGL-1 interactingwith P-selectin and/or E-selectin on endothelial cells and adherentplatelets. This interaction results in “rolling” of the white blood cellon the endothelial cell surface followed by stable adhesion andtransmigration of the white blood cell into the inflamed tissue.

Human PSGL-1 (GenBank Acc. No Q14242.1; GI 2498904) is a mucin-like,homodimeric, disulfide-bonded, glycoprotein that is expressed on thesurface of most hematopoietic cells, including, e.g., neutrophils,monocytes, lymphocytes, dendritic cells, and platelets.

The amino acid sequence of human PSGL-1 shows an amino terminal signalpeptide (amino acid residues 1-17) and a propeptide (amino acid residues18-41) with a consensus cleavage site for paired basic amino acidconverting enzymes (PACE). The N-terminal extracellular region of themature protein begins at residue 42. The extracellular domain of thePSGL-1 molecule contains several serine/threonine rich decameric repeatscontaining multiple O-glycosylation linkage sites and also someN-glycosylation linkage sites. This region of the molecule, which foldsinto a rod-like structure, is responsible for the mucin-likecharacteristics of PSGL-1. On neutrophils, this rod-like structure andthe localization of PSGL-1 on the tips of microvilli facilitates thebinding of PSGL-1 to selectin-expressing cells. The decameric repeatregion of PSGL-1 is followed by the transmembrane region (residues268-292) and the cytoplasmic domain (residues 293-361).

The expression of recombinant PSGL-1 first achieved by Sako et al.(Cell, 1993, 75(6), 1179-1186) has allowed to define regions andmodifications relevant to selectins binding, which have been reported,just to mention somein: Liu et al J. Biol. Chem. 1998, 12:7078-7087,Cummings R D, Brazilian Journal of Medical and Biological research,1999, 32:519-528, Sako et al. Cell, 1995, 83: 323-331 etc., cited ahead.From the overall studies on PSGL-1, regions important for selectinsbinding have been mapped in the N-terminal portion of the mature PSGL-1and encompass residue 5-16 with the three tyrosine sulfation sites andthe O-linked oligosaccharide bearing sLe^(x) located at Thr 16.

The complex post-translational modification pattern of PSGL-1 (theprotein requires two distinct post-translational modifications for theCa²⁺-dependent recognition by the lectin domain of P-selectin: tyrosinesulfation and a specific core 2 O-linked glycosylation by fucose andsialic acid) requires this molecule to be expressed in recombinanteukaryotic systems. Fugang Li et al. J. Biol. Chem, 1996, 271:3255-3264describe the requirements for the recombinant expression of thecorrectly glycosylated form of rPSGL-1. U.S. Pat. No. 5,827,817 and U.S.Pat. No. 6,277,975 describe several variants of the PSGL-1 protein,among which the PSGL-1-Fc IgG1 fusion protein, and their expression inCHO and COS cells in combination with a fucosyl-transferase gene (FT).Thus, PSGL-1 chimerae with portions of the immunoglobulin Fc fragmenthave already been expressed either in CHO or COS carrying suitableenzyme(s) for correct glycosylation.

The same Applicant has already found that a shorter variant of such aPSGL-1 IgG1 Fc fusion protein, covalently bound to phospholipids ofultrasound imaging microvesicles, shows an improved binding to thetarget and increases microbubbles stability. These findings aredisclosed in WO2012/020030 by the same Applicant of the presentinvention.

The present Application discloses the recombinant expression of a PSGL-1chimeric protein which relies on a non-covalent dimerization domains forthe production a homodimeric form of the PSGL-1 fusion protein, by whichthe use of antibody Fc fragments and the drawbacks of the presence ofsuch fragments are avoided. In fact, the recombinant construct of thepresent invention exploits the use of functional fragments of DNAregulatory proteins, the “leucine zippers”, which promoteprotein-protein interactions and homo- or hetero-dimers/multimers, formunder which they act as Transcription Factors, able to interact with DNAand regulate its expression.

Leucine zippers are protein domains with leucine repetitions at every7^(th) (sometimes 4^(th)) amino acid position, able to form aright-handed α helix by which they promote oligomerization withidentical or different counterpart(s), thus generating homo- orhetero-dimers/multimers and the DNA expression regulatory properties.

The use of leucine zippers as dimerization domains in E. coli has beenexploited to produce dimeric antibodies or their functional fragments,ScFv, F(ab′)2. The preparation of bi-functional ScFv in De Kruif, J. andLogtenberg T., J. Biol. Chem., 1996, 271:7630-7634.

GCN4, a yeast leucine zipper has been used in Chingwei V. Lee et al., J.Immunological Methods, 2004, 284: 119-132, for the phage display ofF(ab′)₂ fragments in the M13 system in E. coli.

WO2005/105840, dealing with recombinant CD40, proposes the use of socalled “fusion partners”, to induce oligomerization of CD40 variants ineukaryotic cells. Mannose Binding Protein, the collagen binding domainof tetranectin and leucine zippers, including the Neural Retina-specificLeucine zipper, NRL (GenBank Acc. N. M81840), are enlisted as possiblefusion partners.

The Applicant has now found that when PSGL-1 functional fragments arecloned upstream of a NRL sequence, they are not only correctly processedand expressed as functional homodimers, but also expression andsecretion occur very efficiently, much more than that observed forPSGL-1 Fc-derived constructs with the standard IgG backbone carrying theHinge region and the Fc, commonly used for dimeric protein expression,which has become the reference standard of PSGL-1 homodimer expression.

The present invention allows now the preparation of a P/E Selectinspecific reagent in suitable quantities and with a standard quality forin vivo use in either therapeutic or diagnostic applications.

The chimeric protein can be expressed at high levels in the CHO cellsystem, recognized with safe use properties for the production ofrecombinant proteins and which can provide the glycosylation andpost-translational processing required for selectins binding. The highexpression levels and the functional post-translational processing allownow the industrial scale-up of this reagent.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Western-blot of the conditioned medium from Variants 1-5 underreducing and non-reducing conditions. Lanes 1 and 6: variant 5,respectively under reducing and non-reducing conditions; lanes 2 and 7:Variant 1, respectively under reducing and non-reducing conditions;lanes 3 and 8: Variant 2, respectively under reducing and non-reducingconditions; lanes 4 and 9: Variant 3, respectively under reducing andnon-reducing conditions; lanes 5 and 10: Variant 2, respectively underreducing and non-reducing conditions. MW markers are on the left.

FIG. 2. SPR Biacore (protein binding response on P-selectin) comparisonbetween Fragment 1 (Fr-1, solid line) and the chimeric protein of theinvention (Variant 1A, hatched line) at 125 nM each. Y axis: ResonanceUnit (RU) response including association/dissociation/regeneration as afunction of time (secs) on the X axis.

FIG. 3. Ultrasound imaging of rat inflammatory hind limbs. Images wereobtained with Fixed Bubble Imaging (FBI), 10 minutes after Fragment-1 orVariant 1A microbubble injection.

FIG. 4. Optical imaging of mice hind limb inflammatory LPS model afterinjection of liposomes loaded with either Variant 1A-liposomes-DIR (mice1 to 6) or Fr-1-liposomes-DIR (mice 7 to 12).

The fluorescent images were obtained two hours after liposome injection(left paw: inflamed paw; right paw: contralateral paw).

FIG. 5. RP-HPLC analysis of the final pool of fractions after HApurification described in Example 13 (negative). The Retention time (Rt)of the target protein is about 9.7 min.

SUMMARY OF THE INVENTION

The present invention disclose a recombinant chimeric P-SelectinGlycoprotein Ligand-1 (PSGL-1) protein comprising at least a selectinBinding domain, a leucine zipper domain and a disulfide bonds promotingregion, where the selectin binding region preferably comprises at leastaa 5-16 of SEQ ID NO:11.

The leucine zipper domain comprises an amino acid sequence at least 90%homologous or identical to aa 187-208 of SEQ ID NO:12 (NeuralRetina-specific Leucine Zipper), or more preferably at least 90%homologous or identical to aa 181-215 of SEQ ID NO:12.

In the recombinant chimeric PSGL-1 protein of the invention, thedisulfide bonds promoting region (covalent dimerization domain)comprises an amino acid sequence defined by the following generalformula:

(X₁)n-C(X₂)m-(X₃) wherein:

-   -   X₁, X₂ represents any amino acid or amino acid sequence with the        exclusion of cysteine (Cys),    -   C is Cys    -   X₃ is any amino acid and    -   n, m are integer numbers comprised from 1-6,        or is preferably (SEQ ID NO:20).

The recombinant chimeric protein is a dimeric protein comprising tworecombinant chimeric PSGL-1 monomers as defined above, covalently linkedto each other by at least a disulfide bond and is preferably ahomodimer.

It is expressed in a mammalian system where it is correctlypost-translationally modified and secreted into the culture medium athigh levels as a soluble dimer.

The invention further comprises the DNA sequence encoding for therecombinant chimeric protein as defined above and eukaryotic expressionvectors driving its expression in a mammalian system, preferably CHOcells. The mammalian expression system further comprises theglycosylating enzymes beta 1,6 N-acetylglucosaminyltransferase (C2GnT)and fucosyl-transferase VII (FTVII) on a different or the sameexpression vector for proper glycosilation.

Accordingly, the invention further comprises the mammalian celltransformed with the DNA encoding for the chimeric recombinant PSGL-1protein or the vector as defined above and the isolated purified proteinsecreted by the mammalian cell.

The isolated chimeric protein is homodimeric, O-linked glycosylated atleast on Thr at position 16 and sulfated at least on Tyr at positions 5,7 and 10 of SEQ ID NO:11.

The protein is a useful targeting agent for diagnostic or therapeuticmoieties to which it can be conjugated by linker or spacer comprisingthe amino acid Cys or Lysine, preferably present and placed at theC-terminus.

Diagnostically useful moieties are preferably selected from the groupconsisting of: a radiolabel, an enzyme, a fluorescent label aluminescent label, a metal chelating compound, a gas-filled lipidmicrovesicle and combination of the diagnostically active moieties, andare more preferably metal chelating compounds or gas-filledmicrovesicles. These conjugates are useful for imaging by ultrasound,magnetic resonance, optoacoustic, scintigraphy, Single Photon EmissionComputed Tomography (SPECT), Positron Emission Tomography (PET), X-Ray,radiofrequency acoustic and optical and in pathologic conditionscharacterized by overexpression of a selectin, such as: Acute CoronarySyndrome (ACS), Inflammatory Bowel Disease (IBD), Ulcerative colitis,Crohn's disease, neo-angiogenesis associated with tumors, rheumatoidarthritis, ischemia reperfusion injury, graft rejection or, more ingeneral, of any organ or tissue expressing P-selectin and/or E-selectinabove physiological levels. More preferably the pathologic condition isIBD, ACS, tumour detection or graft rejection.

More preferably, the chimeric protein of the invention is a usefultargeting agent for IBD, ACS, tumour detection and graft rejection.

The therapeutically active moiety is preferably selected in the groupconsisting of: cytokine, cytostatic agent, toxin, anti-inflammatoryagent, immunomodulator, antiaggregant, corticosteroid, monoclonalantibody, growth factor or radiotherapic agents comprising metalchelating moieties to carry a radionuclide.

Further comprised in the invention are pharmaceutical compositionscomprising the recombinant chimeric protein or its conjugates fordiagnostic or therapeutic purposes, as defined above.

A further embodiment of the invention is a process for preparing therecombinant chimeric protein of the invention which comprisestransforming a eukaryotic cell with the DNA sequence encoding for it orthe eukaryotic expression vector comprising said DNA sequence to achievea recombinant system stably expressing the chimeric protein, harvestingthe culture medium and purifying the recombinant protein from saidculture medium.

The invention further relates to a purification process of therecombinant soluble protein, comprising hydroxyapatite as the lastchromatographic step. Hydroxyapatite, preferably Ceramic Hydroxyapatiteis preferably carried out after a strong anion exchange and ahydrophobic interaction chromatography.

Further embodiments of the invention are methods for the therapeutictreatment of a pathologic condition characterized by the overexpressionof a selectin, using the targeting conjugates comprising the recombinantsoluble chimeric protein according to the invention and the diagnosticimaging of a pathologic condition characterized by overexpression of aselectin, which comprises pre-administering the diagnostic conjugates orthe pharmaceutical compositions to a subject and recording the image byan imaging method. Such imaging methods are preferably selected in thegroup consisting of: ultrasound, magnetic resonance, optoacoustic,scintigraphy, Single Photon Emission Computed Tomography (SPECT),Positron Emission Tomography (PET), X-Ray, radiofrequency acoustic andoptical.

Pathologic conditions characterized by overexpression of a selectin arepreferably selected in the group consisting of: Acute Coronary Syndrome(ACS), Inflammatory Bowel Disease (IBD), Ulcerative colitis, Crohn'sdisease, neo-angiogenesis associated with tumors, rheumatoid arthritis,ischemia reperfusion injury, graft rejection or, more in general, of anyorgan or tissue expressing P-selectin and/or E-selectin abovephysiological levels. More preferably the pathologic condition is IBD,ACS, cancer or graft rejection.

DETAILED DESCRIPTION OF THE INVENTION Definitions

Unless otherwise provided, the amino acid and nucleotide sequence of thehuman PSGL-1 to which the present invention refers, is identified byGenBank Acc. No Q14242.1. This Acc. Number identifies also functionaldomains, such as the signal peptide region of PSGL-1, comprised from aa1-17, the pro-peptide region comprised from aa 18 to 41, whichidentifies the start of the mature protein at aa 42 (corresponding to aa1 of SEQ ID NO:11), the N- and O-glycosylation sites and the sulfationsites.

The neural Retina-specific leucine zipper (NRL) amino acid sequence isidentified by NCBI Acc. No NP_006168.1 (GI:1709348, human). In thepresent invention reference to Neural Retina-specific Leucine zipperprotein (NRL) comprises all amino acid sequences at least 90% homologousin the leucine zipper region of NRL, including mouse NRL (P54846).

NRL, first isolated and characterized by Swaroop et al. Proc. Natl.Acad. Sci., 1992, 89: 266-270, single Nucleotide Polymorphisms have beenidentified: they are comprised, if functional, in the present invention;in the NP_006168.1 sequence, the Leucine Zipper domain has beenidentified between amino acids 187-208. Flanking amino acids at theN-term or the C-term of this region, derived from the NRL sequence, mayalso be part of the functional domain (non-covalent dimerization motif).

As used herein, the term “recombinant” is used to describe non-naturallyaltered or manipulated nucleic acids, host cells transfected withexogenous nucleic acids, or polypeptides expressed non-naturally,through manipulation of isolated DNA and transformation of host cells.Recombinant is a term that specifically encompasses DNA molecules whichhave been constructed in vitro using genetic engineering techniques, anduse of the term “recombinant” as an adjective to describe a molecule,construct, vector, transfected cell, polypeptide or polynucleotideincludes such molecules, constructs, vectors, cells, polypeptides orpolynucleotides even if they have a partial sequence identical to thenaturally occurring molecule.

The term “polypeptide” is used to refer to a compound of two or moreamino acids joined through the main chain (as opposed to side chain) bya peptide amide bond (—C(:O)NH—). The term “peptide” is usedinterchangeably herein with “polypeptide” but is generally used to referto polypeptides having fewer than 40, and preferably fewer than 25 aminoacids.

The term “protein” is used to refer to a compound of more than 40 aminoacids joined through the main chain (as opposed to side chain) by apeptide amide bond (—C(:O)NH—).

The term “chimeric protein” or “fusion protein” or “chimera” as used inthe present invention comprises a PSGL-1 polypeptide operatively linkedto at least one non-PSGL-1 polypeptide. A “PSGL-1 polypeptide” sharesthe amino acid sequence of PSGL-1, preferably human, whereas the“non-PSGL-1 polypeptide” has an amino acid sequence which is notsubstantially homologous to PSGL-1 and which is derived from the same ordifferent organism. In a preferred embodiment, the “PSGL-1 polypeptide”comprises the extracellular portion of PSGL-1, or shorter fragmentsthereof, still binding selectins (in particular P and E selectin), suchas the 1-47 fragment of PSGL-1 (SEQ ID NO:11) encompassing aa 5-16,region which defines the selectin binding region. The selectin bindingregion may optionally comprise flanking amino acid(s) at the N- orC-terminus of aa 5-16 derived from the PSGL-1 sequence.

The “fusion” or “chimeric protein” is expressed and produced in arecombinant system by operatively linking the DNA sequence encoding thePSGL-1 polypeptide to the DNA sequence encoding the non-PSGL-1polypeptide fused in frame to each other under the control of regulatoryregions of eukaryotic expression, such as a promoter or apolyadenilation site.

The term “binding” refers to the determination by standard assays,including those described herein, that a binding polypeptide recognizesand binds reversibly to a given target. Such standard assays include,but are not limited to, equilibrium dialysis, gel filtration, surfaceplasmon resonance, immuno affinity assays, including competitiveimmunoassays and the monitoring of spectroscopic changes that resultfrom binding.

A “labeling group” or “detectable label,” as used herein, is a group ormoiety capable of generating a detectable signal. Particularly preferredare labels useful for diagnostic imaging, i.e. labels detectable bymagnetic resonance, radioactive detection, ultrasound, X-ray, light(either UV, infrared, fluorescent, etc.) or carrying a moiety, such as aradioactive metal or other entity, that may be used in radiotherapy orother forms of therapy. Specific labels will be detailed in thefollowing.

The term “specificity” refers to a binding polypeptide having a higherbinding affinity for one target over another. Binding specificity may becharacterized by a dissociation equilibrium constant (K_(D)) or anassociation equilibrium constant (K_(a)) for the two tested targetmaterials. In a preferred embodiment, binding polypeptides of theinvention have a dissociation constant for a desired target that islower than about 10 μM, more preferably lower than about 1 μM, and mostpreferably less than about 0.5 μM or even lower. The term “selectinspecificity” refers to a PSGL-1 binding moiety having a higher affinityfor at least one selectin among P, L, E selectin than an irrelevanttarget.

The term “patient” as used herein refers to any mammal, especiallyhumans.

The term “pharmaceutically acceptable” carrier or excipient refers to anon-toxic carrier or excipient that may be administered to a patient,together with a compound of this invention, and which does not destroythe pharmacological activity thereof.

The term “target” or “target molecule” refers to any substance that abinding moiety or binding polypeptide can bind to, such as proteins orpolypeptides, cells, receptors, carbohydrates, lipids, etc. As usedherein, “target” includes the family of Selectins either in the isolatedform or expressed in or on the surface of a cell, tissue or organ.Accordingly, “targeting” moiety as used herein, refers to a PSGL-1protein or functional fragments thereof capable of binding to selectins,preferably P and E-selectins, if not specified differently.

The terms “therapeutic agent” or “therapeutic” refer to a compound or anagent having a beneficial, therapeutic or cytotoxic effect for i.e.malignant cells in vivo. Therapeutic agents include those compositionsreferred to as, for example, bioactive agents, cytotoxic agents, drugs,chemotherapy agents, radiotherapeutic agents, genetic material, etc.

The term “positively charged” amino acid refers to amino acids in thefollowing group: Arginine, Histidine, Lysine. These amino acids areusually considered as “interchangeable” meaning that substitution of aresidue with another in the same group is usually well tolerated withina protein or polypeptide, even if this may not apply when the residue iscomprised in a critical domain of the protein (such as a alpha-helix, abinding pocket, a sterically-dependent constraint etc.)

The term “negatively charged” amino acid refers to amino acids in thefollowing group: aspartic acid and glutamic acid. These amino acid areusually considered as “interchangeable” meaning that the substitution ofa residue with another in the same group is usually well toleratedwithin a protein or polypeptide, even if this may not apply when theresidue is comprised in a critical domain of the protein (such as abinding pocket or a sterically-dependent region constraint, etc.)

The term amino acid with “polar uncharged side chain” refers to aminoacids in the following group: Serine, Threonine, Asparagine andGlutamine. These amino acids are usually considered as “interchangeable”meaning that the substitution of a residue with another in the samegroup is usually well tolerated within a protein or polypeptide, withthe above mentioned exemplary exceptions.

The term amino acid with “hydrophobic side chain” refers to amino acidsin the following group: Alanine, Valine, Isoleucine, Leucine,Methionine, Phenylalanine, Tyrosine and Tryptophan. These amino acidsare usually considered as “interchangeable” meaning that thesubstitution of a residue with another in the same group is usually welltolerated within a protein or polypeptide, even if this may not applywhen the residue is comprised in a critical domain of the protein (suchas a alpha-helix, a binding pocket, a sterically-dependent constraintetc.).

Amino acids with specific functions in the protein are those comprisedin the following group: Cysteine, Glycine and Proline. Depending onwhether the function is performed due to the size of the residue,glycine may be replaced by other small sized residues, such as Serine orAlanine. At variance, Cysteine may not be replaced when involved in adisulfide bridge.

By covalent dimerization domain, the Applicant refers to a sequence ofamino acids comprising a Cysteine which can be engaged in a disulfidebridge with another cysteine on a different polypeptide chain(extra-chain disulfide bridge), stable in the extracellular environment.

By non-covalent dimerization domain the Applicant refers to a sequenceof amino acids able to determine and/or favor protein-proteininteractions. Preferred non-covalent dimerization domains are structuralalpha-helix, determined by periodic repetition of leucine residues,usually referred to in the art as “leucine zippers”.

Leucine zipper amino acid regions which can be used according to theinvention, are preferably devoid of any lysine (K or Lys). Leucinezipper domain are usually easily identified in eukaryotic “regulatory”proteins, by a periodic repetition of the aa leucine. Among them, i.e.the leucine zipper of Q9Y2D1, corresponding to aa 236-250, or theleucine zipper of the Activating transcription factor 5 (GI:114678546).

However, preferred leucine zippers according to the present inventionare selected in the group consisting of:

-   -   a Neural Retina-specific Leucine zipper protein fragment,        isolated from mammals and sharing a homology degree 90% with        fragment 187-208 of the human NRL protein, even more preferably        the leucine zipper domains of mouse NRL (Q543Y0) or human NRL,        isophorm 2 (P54845-2) or bovine protein F1N4J1.

DETAILED DESCRIPTION

The invention refers to a recombinant PSGL-1 chimeric protein comprisinga Selectin Binding domain and a non-covalent dimerization domain, whichis a leucine zipper and is more preferably the leucine zipper domain ofthe human or mouse Neural Retina-specific Leucine Zipper, preferablycorresponding to at least region 187-208 of NP_006168.1 (SEQ ID NO:12),or more preferably, at least region 181-215 of SEQ ID NO:12.Alternatively, the non-covalent dimerization domain shares a homologydegree 90% with fragment 187-208 of the human NRL protein, even morepreferably is the leucine zipper domains of mouse NRL (Q543Y0) or humanNRL, isophorm 2 (P54845-2) or bovine protein F1N4J1.

By P-selectin Binding Domains, we herein refer to peptides orpolypeptides comprising an amino acid sequence with binding affinity forselectins (“active sequences”), particularly for P-selectin; said activesequences comprise at least amino acids 5-16 (Cummings R D, BrazilianJournal of Medical and Biological research, 1999, 32:519-528) or arepreferably selected among fragments 1-19, 5-41 and 1-47 of SEQ ID NO:11where amino acid 1 represents the first amino acid of the mature PSGL-1protein and corresponds to aa 42 of the GenBank record Acc. N. Q14242.1.

The PSGL-1 protein is a transmembrane homodimer linked by a disulfidebond at Cys 320, close to the transmembrane domain, as defined in theGenBank record.

Up to now, dimerization of recombinant PSGL-1 has been achieved byintroducing the IgG1 Fc domain downstream a PSGL-1 selectin-bindingdomain. The Fc domain comprises a Hinge region carrying at least twocysteines, engaged in disulfide bridges to covalently associate thechimeric protein in homodimers. The immunoglobulin Fc region has beenused in several recombinant systems to improve or to facilitatedimerization that is essential for selectins binding.

However, the presence of the Fc domain presents some drawbacks. First,it was demonstrated that the PSGL-1 fused to a Fc domain, bound at thesurface of the gas microvesicles elicits the formation of aggregates(WO2012/020030). Moreover, the Fc domain might also trigger immunereaction, through specific recognition of Fc-Receptor expressed bymacrophages. This could lead either to the clearance of the moleculecarrying the Fc protein fragment from the blood circulation, or triggeran immune response such as allergic reactions.

As a matter of fact, the same Applicant of the present invention hasfound that a shorter Fc region provides improved properties to thederivatives used for microbubble preparation. Such drawbacks have beenovercome by the present invention, wherein the Leucine zipper domain ofhuman NRL replaces the Fc region. This region is preferably the leucinezipper domain of Neural Retina-specific Leucine Zipper, comprising atleast aa 187-208 of NP_006168.1 or preferably aa 186-209, 185-210,184-211, 183-212, 182-213, 181-214, 181-215, 186-208, 186-210, 187-208or any fragment comprising at least aa 187-208 plus additional 1, 2, 3,4, 5, 6 or 7 flanking amino acids at the N- or C-terminus or both, fromregion 181-215 of the sequence NP_006168.1 (SEQ ID NO:12).

The Applicant has found that the leucine zipper domain of the DNAregulatory proteins NRL, not only allows an efficient covalentdimerization of the chimeric monomer by favouring disulfide bridgeformation, but also provides for a very efficient expression andsecretion of the dimeric functional protein in mammalian recombinantsystems.

Even more surprisingly, this new chimeric protein is correctlypost-translationally modified, i.e. is correctly O-glycosylated andsulfated at Tyr in the expected PSGL-1 region, is dimeric and covalentlybound by disulfide bridge(s) and binds selectin targets with an affinitysuperior or at least equivalent to optimized Fragment 1 (Fr-1),described in WO2012/020030. These conclusions have been obtained by anumber of data which have been better detailed in the experimental part.

The above findings are quite surprising since the present chimericprotein (P-selectin glycoprotein ligand-1 and Neural Retina-specificLeucine Zipper), herein named sPSGL-1-NRL, is the combination of domainsfrom unrelated proteins and is even more peculiar when compared to theexpression levels of other chimeric proteins engineered to carry thePSGL-1 selectin binding domain as the N-terminal region, fused in framewith other dimerization domains commonly used in the art, such as theIgG1 Fc fragment.

Specifically, in one of the preferred embodiments of the invention, thePSGL-1 domain 1-47 of SEQ ID NO:11 has been fused in frame with:

-   -   a covalent dimerization domain, comprising at least a cysteine        as below defined, preferably followed or alternatively preceded        and fused in frame with a non-covalent dimerization domain (or        stabilization domain), such as the NRL leucine zipper, instead        of the Fc or CH3 domain of human IgG1;    -   optionally and preferably a spacer at the C-terminus, to avoid        any sterical hindrance with groups or moieties which are to be        linked at the C-term, and    -   a signal peptide for secretion at the N-terminus of the chimeric        protein, which is suitable to be cleaved off in the mature        chimeric protein and which is preferably not the endogenous        PSGL-1 signal and pro-peptide sequence.

Among the several Variants that have been produced and tested forexpression in a mammalian system: Variant 1 and 1A representingpreferred embodiments of the present PSGL-1-NRL chimeric proteininvention (SEQ ID NO:2 and SEQ ID NO:37), Variant 2 (SEQ ID NO:4), whichcorresponds to the PSGL-1 fused in frame with the human IgG1 Hinge andCH3 domain, used respectively as a covalent and non-covalentdimerization (or stabilization) domains, or Variant 5 (SEQ ID NO:10),comprising the same functional domains of the optimized Fragment 1described in WO2012/020030 prepared for comparative purposes. Of note,in the protein variants of interest, the sequence listings mentionedabove identify a signal peptide which is cleaved off in the expressedmature form.

In particular, it has been observed that only the NRL leucine zippercontaining Variant 1, provides expression levels which are suitable forthe production of a pharmaceutical agent. Comparative data of therelative expression of Variants 1-5, expressed in the same cell-system,is given in FIG. 1, where the expression level of tagged chimericproteins has been evaluated by transient expression, SDS-PAGE indenaturing and non-denaturing conditions and Western-blot with anantibody directed to a common tag (i.e. the FLAG octapeptide) placed atthe C-terminus.

Therefore, without being linked to a particular theory, it is believedthat the presence of a non-covalent dimerization domain such as aleucine zipper and more preferably the leucine zipper of NRL whichfavours protein-protein interaction, in a protein which isphysiologically a dimer (the PSGL-1), results, by either a favourablefolding or a stabilization effect of the final chimeric protein of thepresent invention, in improved expression levels, which can be furtheroptimized by single clone isolation and stabilization in culture. Titersprovided after a preliminary clonal selection are well above 0.1 g/L.

In the chimeric protein of the present invention, the covalentdimerization domain, alternatively called disulfide bond(s) promotingregion, comprises at least one Cys residue available to form a disulfidebond with another Cys in a monomeric chimeric protein counterpart, sothat the two chimeric protein monomers are covalently bound through atleast one disulfide bridge.

A general formula encompassing the covalent dimerization domain is:

(X₁)n-C(X₂)m-(X₃),

Wherein X₁ and X₂ represent any amino acid or amino acid sequence withthe exclusion of Cys; C is cysteine, X₃ is any amino acid and n and mare integer numbers comprised from 1-6. X₁ preferably comprises aProline, Histidine or Threonine; even more preferably comprises aProline and a Histidine or a Histidine and a Threonine or a Proline anda Threonine. According to a preferred embodiment, X₁ comprises aProline, a Histidine and a Threonine, preferably in this order, and n isat most 5. X₂ is any amino acid or amino acid sequence with theexclusion of Cys and preferably comprises Proline. Preferably X₂ isPro-Pro; X₃ is preferably Cysteine and comprises at least a Proline.More preferably, the cysteine carrying region is the IgG1 Hinge region,or functional fragments thereof. A preferred disulfide bonds promotingregion is: PHTCPPCP (SEQ ID NO:20).

According to a preferred embodiment, the chimeric protein furthercomprises a spacer at the C-term, which comprises a residue suitable forcovalent bio-conjugation with other peptide or chemical moieties, suchas imaging and/or therapeutic moieties. Exemplary amino acids forbio-conjugation are cysteine and lysine. The spacer is about 4-20 aminoacids in length and comprises one or more amino acid selected from thegroup consisting of: Gly, Ser, Pro, Ala, Val, Leu; it carries a cysteineor a lysine at its C-terminus, preferably in the penultimate position.The spacer is preferably a poly-glycine embedding an alanine or otherneutral amino acid, such as valine or similar and it carries a cysteineor a lysine, preferably a lysine, wherein said conjugation amino acid isfollowed by Gly, Ser, Pro, Ala, Val, Leu, preferably at least one Gly.The spacer has preferably sequence G₄AG₄KG (SEQ ID NO:17).Alternatively, the chimeric protein comprises a Flag sequence at itsC-terminus, i.e. for identification and purification purposes. Flagsequences are commonly used by the skilled artisan and known in thefield. One example is the DYDDDDK sequence (SEQ ID NO:35), which allowsprotein recognition and/or purification by immuno-affinity with suitableantibodies.

According to a preferred embodiment, the monomeric protein is translatedas a precursor with the signal peptide and is then processed and finallysecreted into the culture medium (conditioned medium) as a homodimerafter cleavage of the signal peptide.

A signal peptide for secretion is present at the N-terminus of theprecursor of the chimeric protein. Preferably, the signal peptide is themouse IgH signal peptide, which has sequence: MEWSWWVFLFFLSVTTGVHS (SEQID NO:18). Other signal peptides (or leader peptides) may be used, suchas the PSGL-1 endogenous signal peptide sequence or other heterologoussignal peptides sequences commonly used in the art of recombinantprotein expression, allowing secretion of post-translationally processedrecombinant proteins. An example of some signal (or leader) peptidesknown in the field has been provided in Table 1.

TABLE 1 Leader signal peptide sequences. Acc. N Name Gene SpecieSequence P01728 LV2A_ Ig  Mus MAWTSLILSLLALCSGASS MOUSE lambda-2musculus SEQ ID NO: 21 chain V region P01758 HVM14_ Ig heavy MusMGWSWIFLFLLSGTAGVHS MOUSE chain V musculus SEQ ID NO: 22 region  108AP01750 HVM06_ Ig heavy Mus MGWSCIILFLVATATGVHS MOUSE chain V musculusSEQ ID NO: 23 region  102 P01749 HVM05_ Ig heavy Mus MGWSCIILFLVATATGVHSMOUSE chain V musculus SEQ ID NO: 24 region 3 P01821 HVM45_ Ig heavy MusMAVLGLLFCLVTFPSCVLS MOUSE chain V musculus SEQ ID NO: 25 region MC101P01748 HVM04_ Ig heavy Mus MGWSCIILFLVAAANGVHS MOUSE chain V musculusSEQ ID NO: 26 region 23 Q61508 ECM1_ Extra- Mus MGTVSRAALILACLALASAMOUSE cellular musculus SEQ ID NO: 27 matrix protein 1 P01751 HVM07_Ig heavy Mus MGWSCIMLFLAATATGVHS MOUSE chain V musculus SEQ ID NO: 28region B1- 8/186-2 P01831 THY1_ Thy-1 Mus MNPAISVALLLSVLQVSRG MOUSEmembrane musculus SEQ ID NO: 29 glyco- protein Q03402 CRIS3_ Cysteine-Mus MALMLVLFFLAAVLPPSLL MOUSE rich musculus SEQ ID NO: 30 secretoryprotein 3 P01746 HVM02_ Ig heavy Mus MGWSFIFLFLLSVTAGVHS MOUSE chain Vmusculus SEQ ID NO: 31 region  93G7 P26262 KLKB1_ Plasma MusMILFNRVGYFVSLFATVSC MOUSE kallikrein musculus SEQ ID NO: 32 P11627L1CAM_ Neural  Mus MVVMLRYVWPLLLCSPCLL MOUSE cell musculus SEQ ID NO: 33adhesion molecule  L1 P06327 HVM52_ Ig heavy Mus MGWRWIFLFLLSGTAGVHCMOUSE chain V musculus SEQ ID NO: 34 region VH558 A1/A4

As an alternative to SEQ ID NO:18 any of the above signal peptides fromSEQ ID NO:24 to SEQ ID NO:34 may be used to achieve secretion of therecombinant protein.

The PSGL-1-NRL chimeric recombinant protein of the present inventionbinds efficiently P/E selectin in a dimeric form where each monomer isthe recombinant PSGL-1 as defined above and is produced in a properlyglycosylated and sulfated form. Several studies published until now,have reviewed the PSGL-1 post-translational requirements for P/E/Lselectin binding i.e. the glycosylation, sulfation, and mapped theresidues important for this processing and for selectin binding (R. DCumming, Braz. J. Biol. Res., 1999, 32(5): 520-528 and D. Sako Cell,1995, 83: 323-331).

In the preferred embodiment of the chimeric protein according to thepresent invention, sialylation (presence of syalic acid) has beenevaluated by Liquid Chromatography coupled to Mass Spectrometry (LC-MS)after a mild acidic treatment. The content of sialyl residues of therecombinant proteins of the invention can be comprised from about 5% to30% w/w, 10% to 28% w/w, 15% to 25% w/w more preferably 15% to 25%.

In order to characterize the recombinant chimeric protein, peptidemapping has been carried out with Asp-N and Chymotrypsin enzymaticdigestion.

N-terminal glutamine (Gln) cyclization to pyroglutamine (pGlu), Tyrsulfation, Thr O-glycosylation (presence of Core 2 SLe^(X)) and dimericstructure have been also assessed and better detailed in theexperimental part.

The dimeric structure of the proteins has been confirmed by chymotrypsincleavage, which provides a (TCPPCPL)₂ fragment according to a preferredembodiment of the recombinant protein.

Sulfation of N-terminal tyrosine (Y) residues 5, 7 and 10 has beenconfirmed by Asp-N digestion. O-glycosilation with a SLe^(X)tetrasaccharide motif has been confirmed on threonine 16 by chymotrypsincleavage.

From all of the above it can be concluded that, in the chimeric proteinsthe N-terminal domain of PSGL-1 important for Selectin binding, isproperly sulfated at Tyr residues corresponding to position 5, 7 and 10of the mature PSGL-1 protein, and glycosylated, in particular O-linkedglycosylated at threonine residue in position 16; O-linked glycanstypically comprise sugar residues such as N-acetylgalactosamine(GalNac), N-acetylglucosamine (GlcNAc), fucose, glucose, galactose,mannose (Man), hexose, xylose, sialic acid or mixtures thereof.

These post-translational modifications (PTM) have been summarized in SEQID NO:38.

The O-linked glycans preferably present on the PSGL-1 portion of thechimeric protein of the present invention are preferably GalNac, GlcNAc,fucose, sialic acid and galactose. O-linked glycans on PSGL-1 arepreferably sialylated and fucosylated and preferably consist of sialylLewis X glycan structure (sLe^(x), sialicacid-galactopyranosyl-fucose-N-acetylglucosamine) bound to threonineresidues.

This type of post-translational modification has been described asessential for P-selectin binding (R. D Cumming, Braz. J. Biol. Res.,1999, 32(5): 520-528 and D. Sako Cell, 1995, 83: 323-331).

Dimers are formed and each monomer is covalently linked by at least onedisulfide bridge to the other.

Correct post-translational processing of the chimeric proteins has beenachieved by expression in mammalian cells such as HEK-293, COS-1 or CHOcells, which have been used in the past for PSGL-1 expression. In anycase, PSGL-1 is preferably co-expressed in mammalian cells together withC2GnT (core 2 β1-6-N acetylglucosaminyltransferase) and either afucosyl-transferase enzyme such as one of the following: Fuc-TIII(Fuc-T: fucosyltransferase), Fuc-IV or Fuc TVII (Fugang Li et al. J.Biol. Chem, 1996, 271:3255-3264) or their functional fragments.Preferably, Fuc TVII or functional fragments thereof are used. Cells,preferably CHO adapted to suspension growth, are allowed to grow for atleast 7 days, usually up to 14 days, using OptiCHO™ (LifeTechnology)medium (other serum-free chemically defined media can be successfullyused, e.g., ActiCHO™ by GE/PAA, FortiCHO™, CellVento™ CHO 200 andCellVento™ CHO 220 by Millipore, 83836C by SAFC, BalanCD™ by Irvine,EX-CELL® by Sigma-Aldrich and the like) and in the absence of selectionpressure. Glutamine (or the analogue GlutMax™) was supplemented at 1-10mM, preferably 4-8 mM. OptiCHO™ and ActiCHO™ (LifeTechnology) arepreferred for expression purposes.

The chimeric protein can be purified to the required purity level by athree steps chromatography comprising: an anion-exchange, a hydrophobicinteraction and size-exclusion or hydroxyapatite (HA) chromatography.Purification comprising a HA column as the last purification step ispreferred and provides a therapeutic grade pure chimeric protein.

Therefore according to a further embodiment, the present inventioncomprises a purification process for the chimeric protein as abovedefined, comprising as the final step a hydroxyapatite (HA)chromatography. More preferably, the purification process comprises afirst chromatography carried out on a strong anion exchange (AE), asecond chromatography carried out on a hydrophobic interaction (HI)solid phase and a third step carried out on HA, preferably Ceramichydroxyapatite.

More generally, the present invention refers to a process for thepurification of any soluble PSGL-1-containing fusion or chimericprotein, wherein said PSGL-1 comprises at least aa 5-16 of the maturePSGL-1 (SEQ ID NO:11), further comprising one or more flanking aminoacid at the N- or C-term of such 5-16 fragment.

More preferably, the PSGL-1 fragment in the chimeric protein comprisesall flanking amino acids up to at least aa 1-47 of the mature PSGL-1.Even more preferably, the chimeric protein further comprises at least aa187-208 of SEQ ID NO:12 (Neural Retina-specific Leucine Zipper) or anamino acid sequence at least 90% homologous or identical to said 187-208region and a covalent dimerization domain as above defined by thegeneral formula. A general embodiment for the chimeric protein has SEQID NO:39.

However, the purification process of the invention comprising HA as thelast step can be successfully applied to any chimeric or recombinantprotein carrying at the N-terminus, the N-terminal region of maturePSGL-1 comprising at least aa 5-16 or 1-47 of PSGL-1.

The process comprising HA as the last purification step allows toachieve purity of the PSGL-1 higher than 95%, preferably 96%, 97%, 98%or 99% from other proteins and substantially free of contaminating DNA,as measured i.e. by commercial DNA quantitation assays, such as the DNAQuantitation Kit, Fluorescence Assay (Sigma).

As for the final yields, the target protein is recovered by the processdescribed above with yields above 50% of the total chimeric targetprotein content, typically above 60% and generally about or above 70%.These yields represent a good result and, most importantly for anindustrial process, they are quite standardized and reproducible withvery low variations.

Standard commercial resins or columns with these features may be usedaccording to the manufacturer's instruction. Ceramic HA is commerciallyavailable i.e. from BIORAD. Purification and elution conditions may beadjusted as known to the skilled man.

For ease of scale-up, the gradient elution can be advantageouslysubstituted with discrete step elution, in order to limit the number ofin-process analyses and reduce the overall process time. The purifiedprotein (purity 90%), in the preferred embodiments of Variant 1 and 1Adescribed below, was characterized and:

-   -   The correct removal of the leader peptide was confirmed;    -   The N-term structure of the PSGL Variant 1A glycoprotein is        mainly in the pyroglutamic form pQATEYEYL. In fact, the use of        Asp N digestion enzyme allowed detecting N-term Gln cyclization,        the process by which the Gln residue present at the N-term, tend        to undergo spontaneous cyclization to form pyroglutamic acid;    -   The dimeric character of the PSGL Variant 1A has been confirmed        by gel electrophoresis in reducing and non-reducing conditions        and enzymatic digestion followed by fragment characterization        using LC-MS. Experimental data shows that PSGL Variant-1A could        be entirely under its dimeric form;    -   The presence of the 0-glycan moiety on Thr16 has been confirmed        and its structure identified. The expected Sialyl-Lewis-X motif,        a Core 2 structure comprising N-Acetylgalactosamine,        N-Acetylglucosamine, galactose, fucose and sialic acid has been        demonstrated, as better detailed in the experimental part;    -   Sulfation of residues Y5, Y7 and Y10 of the mature protein        important for binding to both L- and P-selectin has been also        confirmed. Monitoring of glycoprotein sulfation was performed by        mass spectrometry. As known by the skilled man, sulfation of        Tyrosines 5, 7 and 10, demonstrated in the present target        chimeric protein is extremely important for PSGL-1 and Variant        1A bioactivity. Additional protein characterization data have        been reported in the present Application and better detailed in        the experimental part.

Therefore, according to the main aspect, the invention refers to anisolated and purified PSGL-1 chimeric protein, as above defined, able tobind P, L and E selectins, preferably P selectin.

The isolated recombinant protein is a homodimer wherein each homodimerhas a primary sequence comprising or preferably consisting, of thefollowing amino acid sequences, more preferably in this order:

-   -   amino acid 1-47 of mature PSGL-1 protein (SEQ ID NO:11) at the        N-terminus;    -   at least an amino acid sequence comprising or consisting of a        cysteine suitable for a disulfide bridge with formula:        (X₁)n-C(X₂)m-(X₃), as defined above, more preferably SEQ ID        NO:20;    -   at least aa 181-215 of the NRL (SEQ ID NO:12);    -   optionally, an amino acid spacer up to 15 aa long, carrying: at        least one or more Gly and/or Ala and preferably an amino acid        such as Lys or Cys at the C-terminus or, more preferably, in the        penultimate position. More preferably such a spacer is a        poly-glycine, made of 4, 5, 6, 7, 8, 9 or 10 glycines preferably        comprising and embedding at least an alanine, more preferably        further comprising a lysine in the penultimate position for        further chemical conjugation. Even more preferably the amino        acid spacer is SEQ ID NO:17. Therefore, in a particularly        preferred embodiment, the chimeric protein has sequence SEQ ID        NO:37, where the signal peptide, cleaved off in the mature        protein, is still represented. A post-translationally modified,        chimeric target protein monomer is represented in SEQ ID NO:38        as a preferred embodiment.

A general formula of the chimeric variant protein with motifs or regionsessential for:

-   -   selectin binding, as thoroughly defined above,    -   covalent dimerization (namely a Cys comprising motif with        flanking regions),    -   non-covalent dimerization (namely a motif comprising at least        NRL aa 187-208), preferably comprising residue(s) for        conjugating the chimeric protein, preferably in ultimate or        penultimate position (namely Lys or Cys) has been also reported        in SEQ ID NO:39.

Purity of the isolated and purified PSGL-1 chimeric protein can bedetermined by UPLC-UV or Surface Plasmon Resonance on, i.e., a Biacoreapparatus as better detailed in the Experimental Part.

The present invention also refers to any DNA sequence encoding the aboveprotein in the monomeric form, preferably comprising the nucleotidesequence encoding for amino acid 1-118 of SEQ ID NO:2 of the chimericprotein as defined above.

According to a particularly preferred embodiment the nucleotide sequenceencompasses nt 1-354 of SEQ ID NO:36 and preferably consists ofnucleotide 1-360. Alternatively, the DNA sequence encoding the chimericprotein of the present invention comprises at least the nucleotidesequence encoding the P-selectin Binding domain of PSGL-1, preferably aa1-47 of SEQ ID NO:11 and the nucleotide sequence encoding at least aa187-208 of the Neural Retina-specific Leucine zipper domain (SEQ IDNO:12), optionally comprising 1, 2, 3, 4, 5, 6 flanking amino acids atthe N- or C-terminus, or, more preferably, encoding at least aa 181-215of the NRL (SEQ ID NO:12).

The redundancy of the genetic code allows different codons to be usedfor a single amino acid, thus different combinations of codons, i.e.different DNA sequences, allow to express the protein with the sameprimary amino acid sequence and to produce the same recombinant protein.Such different DNA sequences, which may be designed to optimizeexpression in the selected recombinant system by using preferentialcodons for each organism, are therefore all comprised within the scopeof the present invention.

A particularly preferred recombinant chimeric protein encompasses aa1-118 of SEQ ID NO:2, encoded by nt 1-354 of SEQ ID NO:1. Amino acids1-118 of SEQ ID NO:2 optionally further comprise at the C-terminus atleast an amino acid suitable for chemical conjugation with reactivegroups of a labelling or therapeutic moieties, wherein said amino acidis Lysine or Cysteine. More preferably, such reactive amino acid isfollowed by at least another non-charged amino acid, preferably Glycine.Even more preferably, the amino acid suitable for conjugation is placedat the C-terminus of an amino acid sequence of up to 15 aa and isfollowed by at least one neutral or non-charged amino acid, such asGlycine.

The invention further comprises an expression vector comprising said DNAsequence and the transfected cell clone carrying the recombinantsequence, either transiently or stably integrated into the genome.Preferred cell clones are those carrying stably integrated DNA copies ofthe vector, such as those obtained in CHO cells, more preferably, insuspension-growth adapted CHO cells, which are commercially available,i.e. in the Freedom™ CHO-S™ kit by Lifescience (ThermoFisher Scientific)together with an expression vector standardly used for mammalian cellsexpression.

Suspension-adapted CHO cells can be amplified and grown to a density ofabout 2.10⁷ cells/L, in order to achieve high efficiency secretion ofthe recombinant protein.

According to a further aspect, the invention comprises the process forpreparing the recombinant chimeric protein as defined above, whichcomprises transforming a eukaryotic cell with the DNA sequence encodingit or the vector comprising the DNA sequence encoding it to achieve arecombinant eukaryotic system, preferably a CHO cell system stablyexpressing the chimeric protein and where said chimeric protein ispreferably secreted into the medium, harvesting the culture medium andrecovering the recombinant protein from the said culture medium bypurification.

The purified recombinant chimeric protein can then be successfullyconjugated through the C-term residue to diagnostic and/or therapeuticmoieties or used as such, i.e. in combination with suitable ingredientsor excipients in pharmaceutical compositions.

Conjugates of the Chimeric Protein for Diagnostic and TherapeuticApplications The chimeric protein of the present invention is used totarget diagnostically and therapeutically active moieties linkedthereto, to selectin-expressing tissues, cells or organs. Thespecificity of the chimeric protein that is provided by the PSGL-1region or fragments thereof, targets selectins if properlypost-translationally modified (Liu et al. J. Biol. Chem., 1998,273:7078-7087). It has been confirmed in this expression system, thatthe binding strength to the target is not altered by the presence ofnon-covalent dimerization domains such as leucine zippers which areendowed by a very peculiar secondary structure.

Therefore, according to one of the main embodiments, the presentinvention is directed to conjugates comprising the chimeric protein asthe targeting agent of imaging moieties to selectin expressing cells,tissues, organs etc.

By “imaging moieties” we refer to any moiety detectable by diagnosticimaging procedures, i.e. any diagnostically effective moiety able toprovide, to improve or, in any way, to advantageously modify the signaldetected by an imaging diagnostic technique presently in use, including:ultrasound (US), computed tomography (CT), magnetic resonance imaging(MRI), positron emission tomography (PET), single photon emissioncomputed tomography (SPECT), X-ray imaging, photoacoustic imaging,fluorescence and optical imaging, which in the present invention,comprises intraoperative imaging, i.e any technique enabling theregistration of diagnostically useful, preferably contrasted, images.Hybrid imaging methods are also contemplated in the present invention,where the chimeric protein is linked to at least two moieties detectablewith different imaging methods. Example of hybrid imaging are PET/CT,SPECT/CT, MR/PET, MR/SPECT; ultrasound and MR, ultrasound and CT; MR andCT.

The imaging moiety may comprise any possible combination of the imagingmoieties for dual detection, for example for MRI/PET it may comprise aparamagnetic metal chelating unit and a radionuclide chelating unit.Examples of diagnostically effective moieties according to the inventioncomprise, for instance, chelated gamma ray or positron emittingradionuclides; paramagnetic metal ions in the form of chelated orpolychelated complexes, X-ray absorbing agents including atoms havingatomic number higher than 20; a dye molecule; a fluorescent molecule; aphosphorescent molecule; a molecule absorbing in the UV spectrum; aquantum dot; a molecule capable of absorption within near or farinfrared radiations and, in general, all the moieties which generate adetectable signal or interact specifically with a detection system. Fromall of the above, it is known to the person skilled in the art that theimaging modality to be used has to be selected according to the imagingdetectable moiety the diagnostic compounds of the invention are boundto. So that for example for a fluorescent imaging moiety such as CyC5linked to the chimeric protein, a fluorescence light detection systemwill be appropriate.

The table below provides some exemplary contrast producing agent and thepreferred imaging modality.

TABLE 2 Exemplary contrast producing agents and preferred imagingmodality Modality Contrast-Producing Agent Ultrasound Microbubble,acoustically active liposome CT/X-Ray Gold nanoparticles, iodinatednanoparticles, MRI Hyperpolarized neon/xenon/helium, gadolinium, ironoxide PET ¹⁸F,¹¹C SPECT ^(99m)Tc, ¹²³I, ¹¹¹In Optical Methylene-blue,fluorescent dye such as cyanine-dyes Imaging (Cy7, CyC5, indocyaninegreen) NIR dyes, IRDye800 ® CW, GFP, AlexaFluor ® dyes, microbubble,nano- particle such as liposomes comprising fluorescent dyes DiR, NIRdyes, IRDye800 ® CW, GFP, AlexaFluor ® dyes Photoacoustic Carbonsingle-wall nanotubes (SWINT), indocyanine Imaging green, goldnanoparticles, zinc phthalocyanine.

Conjugation of the Chimeric Protein to Diagnostic and TherapeuticMoieties for Molecular Targeting.

Preparation of conjugates of the chimeric protein of the invention isusually carried out by chemical means.

The reactive groups of the conjugation partners, i.e. the chimericprotein and the group(s) to be conjugated to it, are present or areprepared in a “protected” form. In the present description, unlessotherwise indicated, the term “protecting group” designates a protectivegroup adapted to preserve the characteristic chemical function of thefunctional group to which it is bound. Specifically, in the presentcontext, protective groups are used to preserve amino or carboxylfunctions. Appropriate protective groups may thus include, for example,Fmoc, benzyl, benzyloxycarbonyl or alkyl esters or other groups commonlyintended for the protection of such functions and known to the skilledman.

Other chemical groups, able to chemically react with the N-terminal(—NH₂) or the C-terminal (—COOH) group of a polypeptide unit, such asthe chimeric protein of the invention transforming such group, through achemical reaction, into a suitable derivative maintaining thespecificity of the corresponding polypeptide/protein toward selectin,but unable to chemically react with, respectively, a carboxyl or anamino functionality on a different moiety, are called “de-activatinggroups”. Deactivating groups should not be involved in carboxamidocross-linking reactions. One example is represented by the acetyl-group[also referred to as CH₃(CO)— or even Ac], used to deactivate the aminoterminus of a peptide chain by converting it into the correspondingunreactive acetylated AcHN— group.

On the other end, amino groups themselves and derivatives thereof suchas, for instance, —NH₂, —NH(CH₃) or H₂NOC—CH₂—NH— may be used as“de-activating groups” for the free carboxyl group, by providing thecorresponding —CONH₂, —CONH(CH₃) or —CONH—CH₂—CONH₂ unreactive amides,respectively.

For instance, if the chimeric protein includes a reactive amino group(e.g. a primary amino group of Lysine), it can be reacted with adiagnostic moiety, such as a microvesicle's component containing asuitable corresponding reactive moiety, such as an isothiocyanate group(to form a thiourea bond), a reactive ester (to form an amide bond), acarbonyl group (to form an imine bond, which may be reduced to an aminebond), an activated hydroxyl group, e.g., in the form of a tosylate,tresylated or cyanate, a vinyl sulfone or an epoxide.

Alternatively, when the targeting ligand of the present inventionincludes a reactive thiol group, suitable complementary reactive moietyon the diagnostic or therapeutic moiety, i.e. a microvesicle's componentmay include haloacetyl derivatives, maleimides (to form a thioetherbond) or a mixed disulfide comprising a sulphide in the form of a2-pyridylthio (PDT) group (which, upon reaction with a thiol derivedfrom the targeting ligand, results in the formation of a stabledisulfide bond), an activated hydroxyl group, e.g., in the form of atosylate, tresylated or cyanate, a vinyl sulfone or an epoxide.

Alternatively, according to an embodiment of the invention, a targetingligand containing an amino reactive moiety (e.g. a primary amino group,in particular the terminal —NH₂ group) can be first reacted with asulphur-containing compound, to introduce a reactive thiol moiety in thetargeting ligand, which is then reacted with a correspondingcomplementary moiety on the diagnostic component, i.e. a microvesicle'scomponent as above illustrated. Examples of suitable sulphur-containingcompounds useful for introducing a reactive thiol moiety in a targetingligand containing a reactive amino moiety include, for instance:thioimidate (such as Traut's reagent) N-succinimidyl-S-acetylthioacetate(SATA), N-succinimidyl-S-acetylthiopropionate (SATP) or N-succinimidyl3-(2-pyridyldithio)propionate (SPDP). Detailed description ofS-containing agents and respective thiolation reactions can be found,for instance, in the book by Greg T. Hermanson: “BioconjugateTechniques”, Elsevier ed., 2^(nd) ed. (April 2008), chapter 1, section4-1. For instance, one may prepare a maleimide-derivatized phospholipid(e.g. phosphatidylethanolamine—PE—or pegylated PE) and react it with atargeting ligand (e.g. SEQ ID NO:3) where a primary amino group (e.g.the —NH₂ of Lysine side chain) has been previously reacted with asulphur-containing compound (such as those previously illustrated), tointroduce a reactive thiol moiety; the obtained compound can then beused in the preparation of targeted gas-filled microvesicles.

According to a further alternative, when the targeting ligand includes areactive carboxylic group, suitable reactive moieties on the diagnosticor therapeutic group, i.e. microvesicle's component can be amines andhydrazides (to form amide or N-acyl, N′-alkylhydrazide functions).

According to the above preferred embodiment, the targeting ligandcontaining an amino reactive moiety (e.g. on a Lysine residue), can befirst reacted with a maleimide-containing compound, to introduce areactive maleimide moiety in the targeting ligand, which is then reactedwith a corresponding complementary moiety on the microvesicle'scomponent. Maleimide-containing agents useful for introducing a reactivemaleimide moiety in a targeting ligand containing a reactive aminomoiety and respective reaction of addition of maleimide group are wellknown in the art. Examples of suitable maleimide-containing compoundsinclude, for instance: AMAS (N-(α-maleimidoacetoxy)succinimide ester),BMPS (N-(β-EMCS maleimidopropoxyl)succinimide ester),(N-(ε-maleimidocaproyloxy)succinimide ester), GMBS(N-(γ-maleimidobutyryloxy)succinimide ester), LC-SMCC(succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxy-(6-amidocaproate)),MBS (m-maleimidobenzoyl-N-hydroxysuccimide ester), SMCC(succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate), SMPB(succinimidyl-4-(p-maleimidophenyl)butyrate), SM(PEG)n reagent(succinimidyl-(N-maleimidopropionamido)-ethyleneglycol) ester), SMPH(succinimidyl-6-((β-maleimidopropionamido) hexanoate)), sulfo-EMCS(N-(ε-maleimidocaproyloxy) sulfosuccinimide ester), sulfo-GMBS(N-(γ-maleimidobutyroyloxy)sulfosuccinimide ester), sulfo-KMUS(N-(κ-maleimidoundecanoyloxy)-sulfosuccinimide ester), sulfo-MBS(m-maleimidobenzoyl-N-hydroxysulfo-succinimide ester), sulfo-SMCC(sulfosuccinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate),sulfo-SMPB (sulfosuccinimidyl 4-(p-maleimidophenyl(butyrate)).

Other analogous reagents may contain sulfhydryl reactive groupsdifferent from maleimide, e.g., LC-SPDP (succinimidyl6-[3-2-pyridyldithio)propionamido]hexanoate, NHS-Bromoacetate(N-hydroxysuccinimidyl bromoacetate), NHS-Iodoacetate(N-hydroxysuccinimidyl iodoacetate), SPDP(N-succinimidyl-3-(2-pyridyldithio)propionate), SULFO-LC-SPDP(sulfosuccinimidyl-6-[3-(2-pyridyldithio)propionamido]hexanoate).

According to the microvesicles embodiment for ultrasound diagnosticimaging, one may react a thiol-containing phospholipid (e.g. thiolatedphosphatidylethanolamine—PE—or pegylated PE) with the targeting ligandwhere a primary amino group (e.g. the NH₂ of lysine side chain) has beenpreviously reacted with a thiol reactive compound (e.g., a maleimidesuch as those previously illustrated), to introduce a thiol reactivemoiety therein; the obtained compound can then be used in thepreparation of the microvesicles or other diagnostic or therapeuticconjugates.

In the chimeric protein of the Invention, conjugates are preferablyprepared at the C-terminus of the chimeric protein, leaving theN-terminus available for binding with the selectins target.

Diagnostically Effective Moieties for Ultrasound

Microvesicles

A class of contrast agents, particularly useful for ultrasound contrastimaging, includes suspensions of gas bubbles of nano- and/ormicro-metric size dispersed in an aqueous medium. Of particular interestare those formulations where the gas bubbles are stabilized, for exampleby using emulsifiers, oils, thickeners or sugars, or by entrapping orencapsulating the gas or a precursor thereof in a variety of systems.These stabilized gas bubbles are generally referred to in the art withvarious terminologies, depending typically from the stabilizing materialemployed for their preparation; these terms include, for instance,“microspheres”, “microbubbles”, “microcapsules” or “microballoons”. Theterm “gas-filled microvesicles”, or shortly “microvesicles”, as usedherein includes any of the above terminology.

Gas-Filled Microvesicles

According to a preferred embodiment of the present invention, thegas-filled microvesicles are prepared with lipids or phospholipidscovalently associated to the chimeric protein of the present invention,as selectin targeting ligand and are preferably microbubbles. Bymicrobubbles we refer to bubble of gas suspended in an aqueous carrier,which, at the gas-liquid interface possess a thin envelope (film) with astabilizing amphiphilic material. Examples of aqueous suspensions of gasmicrobubbles are disclosed for instance in U.S. Pat. No. 5,271,928, U.S.Pat. No. 5,445,813, U.S. Pat. No. 5,413,774, U.S. Pat. Nos. 5,556,610,5,597,549, U.S. Pat. No. 5,827,504 and WO 04/069284. The term alsocomprises precursor of microbubbles in the form of freeze-dried orspray-dried component, preferably comprising phospholipid, dispersions.

At variance with microbubbles according to the above definition, theterms “microballoons” or “microcapsules” include suspensions in whichthe bubbles of gas are surrounded by a solid material envelope of alipid or of natural or synthetic polymers. Examples of microballoons andof the preparation thereof are disclosed, for instance, in U.S. Pat. No.5,711,933 and U.S. Pat. No. 6,333,021.

Components suitable for forming a stabilizing envelope of microbubblescomprise, for instance, phospholipids; lysophospholipids; fatty acids,such as palmitic acid, stearic acid, arachidonic acid or oleic acid;lipids bearing polymers, such as chitin, hyaluronic acid,polyvinylpyrrolidone or polyethylene glycol (PEG), also referred as“pegylated lipids”; lipids bearing sulfonated mono-di-, oligo- orpolysaccharides; cholesterol, cholesterol sulfate or cholesterolhemisuccinate; tocopherol hemisuccinate; lipids with ether orester-linked fatty acids; polymerized lipids; diacetyl phosphate;dicetyl phosphate; ceramides; polyoxyethylene fatty acid esters (such aspolyoxyethylene fatty acid stearates), polyoxyethylene fatty alcohols,polyoxyethylene fatty alcohol ethers, polyoxyethylated sorbitan fattyacid esters, glycerol polyethylene glycol ricinoleate, ethoxylatedsoybean sterols, ethoxylated castor oil or ethylene oxide (EO) andpropylene oxide (PO) block copolymers; sterol aliphatic acid estersincluding, cholesterol butyrate, cholesterol iso-butyrate, cholesterolpalmitate, cholesterol stearate, lanosterol acetate, ergosterolpalmitate, or phytosterol n-butyrate; sterol esters of sugar acidsincluding cholesterol glucuronides, lanosterol glucoronides,7-dehydrocholesterol glucoronide, ergosterol glucoronide, cholesterolgluconate, lanosterol gluconate, or ergosterol gluconate; esters ofsugar acids and alcohols including lauryl glucoronide, stearoylglucoronide, myristoyl glucoronide, lauryl gluconate, myristoylgluconate, or stearoyl gluconate; esters of sugars with aliphatic acidsincluding sucrose laurate, fructose laurate, sucrose palmitate, sucrosestearate, glucuronic acid, gluconic acid or polyuronic acid; saponinsincluding sarsasapogenin, smilagenin, hederagenin, oleanolic acid, ordigitoxigenin; glycerol or glycerol esters including glyceroltripalmitate, glycerol distearate, glycerol tristearate, glyceroldimyristate, glycerol trimyristate, glycerol dilaurate, glyceroltrilaurate, glycerol dipalmitate; long chain alcohols including n-decylalcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, or n-octadecylalcohol; 6-(5-cholesten-3β-yloxy)-1-thio-β-D-galactopyranoside;digalactosyldiglyceride;6-(5-cholesten-3β-yloxy)hexyl-6-amino-6-deoxy-1-thio-β-D-galactopyranoside;6-(5-cholesten-3β-yloxy)hexyl-6-amino-6-deoxyl-1-thio-β-D-mannopyranoside;12-(((7′-diethylaminocoumarin-3-yl)carbonyl)methylamino)octadecanoicacid;N-[12-(((7′-diethylaminocoumarin-3-yl)carbonyl)methylamino)octadecanoyl]-2-aminopalmiticacid; N-succinyl-dioleylphosphatidylethanolamine;1,2-dioleyl-sn-glycerol; 1,2-dipalmitoyl-sn-3-succinylglycerol;1,3-dipalmitoyl-2-succinylglycerol;1-hexadecyl-2-palmitoylglycerophosphoethanolamine orpalmitoylhomocysteine; alkylamines or alkylammonium salts, comprising atleast one (C₁₀-C₂₀), preferably (C₁₄-C₁₈), alkyl chain, such as, forinstance, N-stearylamine, N,N′-distearylamine, N-hexadecylamine,N,N′-dihexadecylamine, N-stearylammonium chloride,N,N′-distearylammonium chloride, N-hexadecylammonium chloride,N,N′-dihexadecylammonium chloride, dimethyldioctadecylammonium bromide(DDAB), hexadecyltrimethylammonium bromide (CTAB); tertiary orquaternary ammonium salts comprising one or preferably two (C₁₀-C₂₀),preferably (C₁₄-C₁₈), acyl chain linked to the N-atom through a (C₃-C₆)alkylene bridge, such as, for instance,1,2-distearoyl-3-trimethylammonium-propane (DSTAP),1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP),1,2-oleoyl-3-trimethylammonium-propane (DOTAP),1,2-distearoyl-3-dimethylammonium-propane (DSDAP); and mixtures orcombinations thereof.

Depending on the combination of components and on the manufacturingprocess of the microbubbles, the above listed exemplary compounds may beemployed as the main compound for forming the microbubble's envelope oras simple additives, thus being present only in minor amounts.

According to a preferred embodiment, at least one of the compoundsforming the microbubbles' envelope is an amphiphilic compound (i.e. anorganic molecule comprising both a hydrophilic and lipophilic moiety),preferably a phospholipid, optionally in admixture with any of the otherabove-cited materials. According to the present description, the termphospholipid is intended to encompass any amphiphilic phospholipidcompound, the molecules of which are capable of forming a stabilizingfilm of material (typically in the form of a mono-molecular layer) atthe gas-water boundary interface in the final microbubbles suspension.Accordingly, these materials are also referred in the art as“film-forming phospholipids”.

Amphiphilic phospholipid compounds typically contain at least onephosphate group and at least one, preferably two, lipophilic long-chainhydrocarbon groups.

Examples of suitable phospholipids include esters of glycerol with oneor preferably two (equal or different) residues of fatty acids and withphosphoric acid, wherein the phosphoric acid residue is in turn bound toa hydrophilic group, such as, for instance, choline(phosphatidylcholines—PC), serine (phosphatidylserines—PS), glycerol(phosphatidylglycerols—PG), ethanolamine (phosphatidylethanolamines—PE),inositol (phosphatidylinositol—PI). Esters of phospholipids with onlyone residue of fatty acid are generally referred to in the art as the“lyso” forms of the phospholipid or “lysophospholipids”. Fatty acidsresidues present in the phospholipids are in general long chainaliphatic acids, typically containing from 12 to 24 carbon atoms,preferably from 14 to 22; the aliphatic chain may contain one or moreunsaturations or is preferably completely saturated. Examples ofsuitable fatty acids included in the phospholipids are, for instance,lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid,behenic acid, oleic acid, linoleic acid, and linolenic acid. Preferably,saturated fatty acids such as myristic acid, palmitic acid, stearic acidand arachidic acid are employed.

Further examples of phospholipids are phosphatidic acids, i.e. thediesters of glycerol-phosphoric acid with fatty acids; sphingolipidssuch as sphingomyelins, i.e. those phosphatidylcholine analogs where theresidue of glycerol diester with fatty acids is replaced by a ceramidechain; cardiolipins, i.e. the esters of 1,3-diphosphatidylglycerol witha fatty acid; glycolipids such as gangliosides GM1 (or GM2) orcerebrosides; glucolipids; sulfatides and glycosphingolipids.

As used herein, the term phospholipids include either naturallyoccurring, semisynthetic or synthetically prepared products that can beemployed either singularly or as mixtures.

Examples of naturally occurring phospholipids are natural lecithins(phosphatidylcholine (PC) derivatives) such as, typically, soya bean oregg yolk lecithins.

Examples of semisynthetic phospholipids are the partially or fullyhydrogenated derivatives of the naturally occurring lecithins. Preferredphospholipids are fatty acid di-esters of phosphatidylcholine,ethylphosphatidylcholine, phosphatidylglycerol, phosphatidic acid,phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol or ofsphingomyelin.

Examples of preferred phospholipids are, for instance,dilauroyl-phosphatidylcholine (DLPC), dimyristoyl-phosphatidylcholine(DMPC), dipalmitoyl-phosphatidylcholine (DPPC),diarachidoyl-phosphatidylcholine (DAPC), distearoyl-phosphatidylcholine(DSPC), dioleoyl-phosphatidylcholine (DOPC), 1,2Distearoyl-sn-glycero-3-Ethylphosphocholine (Ethyl-DSPC),dipentadecanoyl-phosphatidylcholine (DPDPC),1-myristoyl-2-palmitoyl-phosphatidylcholine (MPPC),1-palmitoyl-2-myristoyl-phosphatidylcholine (PMPC),1-palmitoyl-2-stearoyl-phosphatidylcholine (PSPC),1-stearoyl-2-palmitoyl-phosphatidylcholine (SPPC),1-palmitoyl-2-oleylphosphatidylcholine (POPC),1-oleyl-2-palmitoyl-phosphatidylcholine (OPPC),dilauroyl-phosphatidylglycerol (DLPG) and its alkali metal salts,diarachidoylphosphatidyl-glycerol (DAPG) and its alkali metal salts,dimyristoylphosphatidylglycerol (DMPG) and its alkali metal salts,dipalmitoylphosphatidylglycerol (DPPG) and its alkali metal salts,distearoylphosphatidylglycerol (DSPG) and its alkali metal salts,dioleoyl-phosphatidylglycerol (DOPG) and its alkali metal salts,dimyristoyl phosphatidic acid (DMPA) and its alkali metal salts,dipalmitoyl phosphatidic acid (DPPA) and its alkali metal salts,distearoyl phosphatidic acid (DSPA), diarachidoylphosphatidic acid(DAPA) and its alkali metal salts, dimyristoyl-phosphatidylethanolamine(DMPE), dipalmitoylphosphatidylethanolamine (DPPE), distearoylphosphatidyl-ethanolamine (DSPE), dioleylphosphatidyl-ethanolamine(DOPE), diarachidoylphosphatidyl-ethanolamine (DAPE),dilinoleylphosphatidylethanolamine (DLPE), dimyristoylphosphatidylserine (DMPS), diarachidoyl phosphatidylserine (DAPS),dipalmitoyl phosphatidylserine (DPPS), distearoylphosphatidylserine(DSPS), dioleoylphosphatidylserine (DOPS), dipalmitoyl sphingomyelin(DPSP), and distearoylsphingomyelin (DSSP),dilauroyl-phosphatidylinositol (DLPI), diarachidoylphosphatidylinositol(DAPI), dimyristoylphosphatidylinositol (DMPI),dipalmitoylphosphatidylinositol (DPPI), distearoylphosphatidylinositol(DSPI), dioleoyl-phosphatidylinositol (DOPI).

Suitable phospholipids further include phospholipids modified by linkinga hydrophilic polymer, such as polyethyleneglycol (PEG) orpolypropyleneglycol (PPG), thereto. Preferred polymer-modifiedphospholipids include “pegylated phospholipids”, i.e. phospholipidsbound to a PEG polymer. Examples of pegylated phospholipids arepegylated phosphatidylethanolamines (“PE-PEGs” in brief) i.e.phosphatidylethanolamines where the hydrophilic ethanolamine moiety islinked to a PEG molecule of variable molecular weight (e.g. from 300 to20000 daltons, preferably from 500 to 5000 daltons), such as DPPE-PEG(or DSPE-PEG, DMPE-PEG, DAPE-PEG or DOPE-PEG). For example, DPPE-PEG2000refers to DPPE having attached thereto a PEG polymer having a meanaverage molecular weight of about 2000.

Particularly preferred phospholipids are DAPC, DSPC, DSPG, DPPA, DSPA,DMPS, DPPS, DSPS and Ethyl-DSPC. Most preferred are DSPG or DSPC.

Mixtures of phospholipids can also be used, such as, for instance,mixtures of DSPE, DPPE, DPPC, DSPC and/or DAPC with DSPS, DPPS, DSPA,DPPA, DSPG, DPPG, Ethyl-DSPC and/or Ethyl-DPPC.

In preferred embodiments, the phospholipid is the main component of thestabilizing envelope of microbubbles, amounting to at least 50% (w/w) ofthe total amount of components forming the envelope of the gas-filledmicrobubbles. In some of the preferred embodiments, substantially thetotality of the envelope (i.e. at least 80% and up to 100% by weight)can be formed of phospholipids.

The phospholipids can conveniently be used in admixture with any of theabove listed compounds. Thus, for instance, substances such ascholesterol, ergosterol, phytosterol, sitosterol, lanosterol,tocopherol, propyl gallate or ascorbyl palmitate, fatty acids such asmyristic acid, palmitic acid, stearic acid, arachidic acid andderivatives thereof or butylated hydroxytoluene and/or othernon-phospholipid compounds can optionally be added to one or more of theforegoing phospholipids in proportions ranging from zero to 50% byweight, preferably up to 25%. Particularly preferred are amphiphiliccompounds, such as C₁₀-C₂₀ carboxylic acids, preferably palmitic acid.

According to a preferred embodiment, the envelope of microbubblesaccording to the invention includes a compound bearing an overall(positive or negative) net charge. Said compound can be a chargedamphiphilic material, preferably a lipid or a phospholipid.

Examples of phospholipids bearing an overall negative charge arederivatives, in particular fatty acid di-ester derivatives, ofphosphatidylserine, such as DMPS, DPPS, DSPS; of phosphatidic acid, suchas DMPA, DPPA, DSPA; of phosphatidylglycerol such as DMPG, DPPG and DSPGor of phosphatidylinositol, such as DMPI, DPPI or DPPI. Also modifiedphospholipids, in particular PEG-modified phosphatidylethanolamines,such as DPPE-PEG or DSPE-PEG, can be used as negatively chargedmolecules. Also the lyso-form of the above cited phospholipids, such aslysophosphatidylserine derivatives (e.g. lyso-DMPS, -DPPS or -DSPS),lysophosphatidic acid derivatives (e.g. lyso-DMPA, -DPPA or -DSPA) andlysophosphatidylglycerol derivatives (e.g. lyso-DMPG, -DPPG or -DSPG),can advantageously be used as negatively charged compounds. Otherexamples of negatively charged compounds are bile acid salts such ascholic acid salts, deoxycholic acid salts or glycocholic acid salts; and(C₁₂-C₂₄), preferably (C₁₄-C₂₂) fatty acid salts such as, for instance,palmitic acid salts, stearic acid salts,1,2-dipalmitoyl-sn-3-succinylglycerol salts or1,3-dipalmitoyl-2-succinylglycerol salts. Preferably, the negativelycharged compound is selected among DPPA, DPPS, DSPG, DPPG, DSPE-PEG2000,DSPE-PEG5000 or mixtures thereof.

The negatively charged component is typically associated with acorresponding positive counter-ion, which can be mono-(e.g. an alkalimetal or ammonium), di-(e.g. an alkaline earth metal) or tri-valent(e.g. aluminium). Preferably the counter-ion is selected among alkalimetal cations, such as Na⁺ or K⁺, more preferably Nat Examples ofphospholipids bearing an overall positive charge are derivatives ofethylphosphatidylcholine, in particular di-esters ofethylphosphatidylcholine with fatty acids, such as1,2-distearoyl-sn-glycero-3-ethylphosphocholine (Ethyl-DSPC or DSEPC),1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (Ethyl-DPPC or DPEPC).The negative counter-ion is preferably a halide ion, in particular achloride or a bromide ion. Examples of positively charged compounds thatcan be incorporated into the envelope of microbubbles are mono-,di-tri-, or tetra-alkylammonium salts with a halide counter ion (e.g.chloride or bromide) comprising at least one (C₁₀-C₂₀), preferably(C₁₄-C₁₈), alkyl chain, such as, for instance mono- ordi-stearylammonium chloride, mono or di-hexadecylammonium chloride,dimethyldioctadecylammonium bromide (DDAB) or hexadecyltrimethylammoniumbromide (CTAB). Further examples of positively charged compounds thatcan be incorporated into the envelope of microbubbles are tertiary orquaternary ammonium salts with a halide counter ion (e.g. chloride orbromide) comprising one or preferably two (C₁₀-C₂₀), preferably(C₁₄-C₁₈), acyl chains linked to the N-atom through a (C₃-C₆) alkylenebridge, such as, for instance,1,2-distearoyl-3-trimethylammonium-propane (DSTAP),1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP),1,2-oleoyl-3-trimethylammonium-propane (DOTAP) or1,2-distearoyl-3-dimethylammonium-propane (DSDAP).

DSEPC, DPEPC and/or DSTAP are preferably employed as positively chargedcompounds in the microbubble envelope.

The positively charged component is typically associated with acorresponding negative counter-ion, which can be mono- (e.g. halide),di- (e.g. sulphate) or tri-valent (e.g. phosphate). Preferably thecounter-ion is selected from among the halide ions, such as F⁻(fluorine), Cl⁻ (chlorine) or Br⁻ (bromine).

Mixtures of neutral and charged compounds, in particular ofphospholipids and/or lipids, can be satisfactorily employed to form themicrobubble envelope. The amount of charged lipid or phospholipid mayvary from about 95 mol % to about 0.1 mol %, with respect to the totalamount of lipid and phospholipid, preferably from 80 mol % to 0.5 mol %.

Preferred mixtures of neutral phospholipids and charged lipids orphospholipids are, for instance, DPPG/DSPC, DSTAP/DAPC, DPPS/DSPC,DPPS/DAPC, DPPE/DPPG, DSPA/DAPC, DSPA/DSPC, DSPC/PA(Distearoylphosphatidylcholine/Palmitic Acid) and DSPG/DSPC.

Any of the above illustrated components useful for forming thestabilizing envelope of the gas-filled microvesicle, in particularphospholipids, preferably pegylated phospholipids, can be modified byinserting a suitable reactive moiety therein, in order to allow bindingsuitable compounds, such as a targeting ligand comprising the sequenceset forth as SEQ ID NO:1, or more preferably a sequence comprising aminoacids 1-118 of SEQ ID NO:1. For instance, a pegylated phospholipid (e.g.DSPE-PEG2000) may comprise a terminal reactive moiety (e.g. maleimide,in brief “mal”, thus forming a DSPE-PEG-mal component) capable of(covalently) reacting with a corresponding reactive moiety on a compoundcomprising the above sequence. Examples of additional suitable reactivemoieties are illustrated in the following of this specification.

According to an alternative embodiment, the targeting ligand componentcan be associated with gas-filled microcapsules. Preferred examples ofmicrocapsules are those having a stabilizing envelope comprising apolymer, preferably a biodegradable polymer, or a biodegradablewater-insoluble lipid (such as tripalmitine) optionally in admixturewith a biodegradable polymer. Examples of suitable microcapsules and ofthe preparation thereof are disclosed, for instance in U.S. Pat. No.5,711,933 and U.S. Pat. No. 6,333,021, herein incorporated by referencein their entirety. Microcapsules having a proteinaceous envelope, i.e.made of natural proteins (albumin, haemoglobin) such as those describedin U.S. Pat. No. 4,276,885 or EP-A-0 324 938 (here incorporated byreference), can also be employed. The targeting ligand can beincorporated into the microcapsules e.g. by binding it to anenvelope-forming component of the microcapsules, according to thepreparation methods illustrated above, or by admixing to the componentsforming the microcapsules envelope an amphiphilic component, as thosepreviously illustrated, covalently bound to targeting ligand.

Other excipients or additives may be present either in the dryformulation of the microvesicles or may be added together with theaqueous carrier used for the reconstitution thereof, without necessarilybeing involved (or only partially involved) in the formation of thestabilizing envelope of the microvesicles. These include pH regulators(such as histidine), osmolality adjusters, viscosity enhancers,emulsifiers, bulking agents, etc. and may be used in conventionalamounts. For instance compounds like polyoxypropylene glycol andpolyoxyethylene glycol as well as copolymers thereof can be used.Examples of viscosity enhancers or stabilizers are compounds selectedfrom linear and cross-linked poly- and oligo-saccharides, sugars andhydrophilic polymers such as polyethylene glycol.

As the preparation of gas-filled microvesicles may involve a freezedrying or spray drying step, it may be advantageous to include in theformulation a lyophilization additive, such as an agent withcryoprotective and/or lyoprotective effect and/or a bulking agent, forexample an amino-acid such as glycine; a carbohydrate, e.g. a sugar suchas sucrose, mannitol, maltose, trehalose, glucose, lactose or acyclodextrin, or a polysaccharide such as dextran; or apolyoxyalkyleneglycol such as polyethylene glycol. Typically, the amountof the lyophilization additive may range from about 10 to about 1000times (w/w) the amount of the microvesicle-forming components.

Any biocompatible gas, gas precursor or mixture thereof may be employedto fill the above microvesicles (hereinafter also identified as“microvesicle-forming gas”). The gas may comprise, for example, air;nitrogen; oxygen; carbon dioxide; hydrogen; nitrous oxide; a noble orinert gas such as helium, argon, xenon or krypton; a radioactive gassuch as Xe¹³³ or Kr⁸¹; a hyperpolarized noble gas such as hyperpolarizedhelium, hyperpolarized xenon or hyperpolarized neon; a low molecularweight hydrocarbon (e.g. containing up to 7 carbon atoms), for examplean alkane such as methane, ethane, propane, butane, isobutane, pentaneor isopentane, a cycloalkane such as cyclobutane or cyclopentane, analkene such as propene, butene or isobutene, or an alkyne such asacetylene; an ether; a ketone; an ester; halogenated gases, preferablyfluorinated gases, such as or halogenated, fluorinated or perfluorinatedlow molecular weight hydrocarbons (e.g. containing up to 7 carbonatoms); or a mixture of any of the foregoing. Where a halogenatedhydrocarbon is used, preferably at least some, more preferably all, ofthe halogen atoms in said compound are fluorine atoms.

Fluorinated gases are preferred, in particular perfluorinated gases,especially in the field of ultrasound imaging. Fluorinated gases includematerials which contain at least one fluorine atom such as, for instancefluorinated hydrocarbons (organic compounds containing one or morecarbon atoms and fluorine); sulfur hexafluoride; fluorinated, preferablyperfluorinated, ketones such as perfluoroacetone; and fluorinated,preferably perfluorinated, ethers such as perfluorodiethyl ether.Preferred compounds are perfluorinated gases, such as SF₆ orperfluorocarbons (perfluorinated hydrocarbons), i.e. hydrocarbons whereall the hydrogen atoms are replaced by fluorine atoms, which are knownto form particularly stable microbubble suspensions, as disclosed, forinstance, in EP 0554213, which is herein incorporated by reference.

The term perfluorocarbon includes saturated, unsaturated, and cyclicperfluorocarbons. Examples of biocompatible, physiologically acceptableperfluorocarbons are: perfluoroalkanes, such as perfluoromethane,perfluoroethane, perfluoropropanes, perfluorobutanes (e.g.perfluoro-n-butane, optionally in admixture with other isomers such asperfluoro-isobutane), perfluoropentanes, perfluorohexanes orperfluoroheptanes; perfluoroalkenes, such as perfluoropropene,perfluorobutenes (e.g. perfluorobut-2ene) or perfluorobutadiene;perfluoroalkynes (e.g. perfluorobut-2-yne); and perfluorocycloalkanes(e.g. perfluorocyclobutane, perfluoromethylcyclobutane,perfluorodimethylcyclobutanes, perfluorotrimethylcyclobutanes,perfluorocyclopentane, perfluoromethylcyclopentane,perfluorodimethylcyclopentanes, perfluorocyclohexane,perfluoromethylcyclohexane and perfluorocycloheptane). Preferredsaturated perfluorocarbons include, for example, CF₄, C₂F₆, C₃F₈, C₄F₈,C₄F₁₀, C₅F₁₂ and C₆F₁₂.

It may also be advantageous to use a mixture of any of the above gasesin any ratio. For instance, the mixture may comprise a conventional gas,such as nitrogen, air or carbon dioxide and a gas forming a stablemicrobubble suspension, such as sulfur hexafluoride or a perfluorocarbonas indicated above. Examples of suitable gas mixtures can be found, forinstance, in WO 94/09829, which is herein incorporated by reference. Thefollowing combinations are particularly preferred: a mixture of gases(A) and (B) in which the gas (B) is a fluorinated gas, selected amongthose previously illustrated, including mixtures thereof, and (A) isselected from air, oxygen, nitrogen, carbon dioxide or mixtures thereof.The amount of gas (B) can represent from about 0.5% to about 95% v/v ofthe total mixture, preferably from about 5% to 80%.

Particularly preferred gases are SF₆, C₃F₈, C₄F₁₀ or mixtures thereof,optionally in admixture with air, oxygen, nitrogen, carbon dioxide ormixtures thereof.

In certain circumstances it may be desirable to include a precursor to agaseous substance (i.e. a material that is capable of being converted toa gas in vivo). Preferably the gaseous precursor and the gas derivedtherefrom are physiologically acceptable. The gaseous precursor may bepH-activated, photo-activated, temperature activated, etc. For example,certain perfluorocarbons may be used as temperature activated gaseousprecursors. These perfluorocarbons, such as perfluoropentane orperfluorohexane, have a liquid/gas phase transition temperature aboveroom temperature (or the temperature at which the agents are producedand/or stored) but below body temperature; thus, they undergo aliquid/gas phase transition and are converted to a gas within the humanbody.

For the use in MRI the microvesicles will preferably contain ahyperpolarized noble gas such as hyperpolarized neon, hyperpolarizedhelium, hyperpolarized xenon, or mixtures thereof, optionally inadmixture with air, carbon dioxide, oxygen, nitrogen, helium, xenon, orany of the halogenated hydrocarbons as defined above.

For use in scintigraphy, the microvesicle will preferably containradioactive gases such as Xe¹³³ or Kr⁸¹ or mixtures thereof, optionallyin admixture with air, carbon dioxide, oxygen, nitrogen, helium, kriptonor any of the halogenated hydrocarbons as defined above.

Metal Chelating Agents for NMR Imaging and Therapy.

The most reliable and most frequently applied method of linking a metalion which can be either the imaging probe or radiotherapic effector, toa biomolecule such as the chimeric protein of the invention, is by meansof bifunctional chelating agents, which carry the metal chelating cageand a reactive group to covalently link the biomolecule.

Metal coordination cages can be divided into cyclic, such as DOTA(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or TETA(1,4,8,11 tetraazacyclododecane-1,4,8,11-tetraacetic acid), or linearsuch as EDTA (ethylendiaminotetraacetic acid) or DTPA(diethylenetriaminopentaacetic acid).

Once the most suitable metal chelating cage, or “chelating ligand” hasbeen selected, conjugation to the biomolecule of interest via a reactivegroup, can be carried out by solid phase synthesis or in solution.Lattuada L. et al. reviews in Chem Soc. Rev, 2011, 40, 3019-3049 thesynthetic approaches for conjugating metal chelating ligands to othermoieties, in particular biomolecules, to prepare targeted metalchelating agents.

According to the embodiment disclosed in this paragraph, the metal iseither detectable by an imaging technique or a radionuclide useful fortherapy. Metals suitable for imaging specifically include paramagneticmetal ions detectable by Magnetic Resonance Imaging (MRI), orradionuclides detectable by imaging techniques such as Scintigraphy,Single Photon Emission Computed Tomography (SPECT) and Positron EmissionTomography (PET).

In this context, the terms: “chelator”, “chelating ligand” or “chelatingagent” comprise chemical moieties, agents, compounds, or moleculescharacterized by the presence of polar groups able to a form a complexcontaining more than one coordinate bond with a transition metal oranother metal. In a preferred aspect of the invention said chelatingligand includes cyclic or linear polyamino polycarboxylic orpolyphosphonic acids and contains at least one amino, thiol or carboxylgroup present as free or optionally activated functionality, suitablefor conjugating the functional groups of the targeting protein or asuitable bifunctional linkers.

Linkers may be used as spacers or to improve the pharmacokineticproperties of the whole molecule. Some of the most frequently usedlinkers have been summarized in Liu S. and Edwards S. Bioconjugate Chem.2001, 12: 7-34 as well as disclosed for peptide conjugation, inWO2008/071679.

With the term “labelled” or “complexed” as used herein i.e. in thecontext of “chelating ligand labelled with a metal”, we refer to aligand that is complexed with the metal, i.e. a ligand that is in theform of a chelate or coordinate complex with the metal element.

With the terms “metal entity” or “metal element”, we refer to a metalion that is detectable by an imaging technique, or radionuclides foreither imaging or therapy.

The term comprises paramagnetic metal ions detectable by MagneticResonance Imaging (MRI) and radiation emitting metals such asradionuclides, detectable by scintigraphic imaging, Single PhotonEmission Computed Tomography (SPECT) and Positron Emission Tomography(PET) or suitable for radiotherapy, as defined below. Suitable chelatingligands are selected from the group consisting of: apolyaminopolycarboxylic acid and the derivative thereof comprising, forexample, diethylenetriamine pentaacetic acid(DTPA) and derivativethereof including benzo-DTPA, dibenzo-DTPA, phenyl-DTPA, diphenyl-DTPA,benzyl-DTPA and dibenzyl DTPA,N,N-Bis[2-[(carboxymethyl)[(methylcarbamoyl)methyl]ethyl]-glycine(DTPA-BMA),N-[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl)]-N-[2-[bis(carboxymethyl)amino]ethyl]glycine (EOB-DTPA),4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oicacid (BOPTA), N,N-bis[2-[bis(carboxymethyl)amino]ethyl]L-glutamic acid(DTPA-GLU); DTPA-Lys (see compound 1 of FIG. 3a );ethylenediaminetetraacetic acid (EDTA); 1,4,7,10-teraazacyclododecane1,4,7,-triacetic acid (DO3A) and derivatives thereof including, forexample, [10-(2-hydroxypropyl)-1,4,7,10-teraazacyclododecane1,4,7,-triacetic acid (HPDO3A); 1,4,7-triazacyclononaneN,N′,N″-triacetic acid (NOTA);6-[bis(carboxymethyl)amino]tetrahydro-6-methyl-1H-1,4-diazepine-1,4(5H)-diaceticacid (AAZTA) and derivative thereof, for instance as disclosed inWO03/008390, incorporated herein by reference,1,4,7,10-tetra-azacyclotetradecane-1,4,7,10-tetraacetic acid (DOTA) andderivatives thereof including, for instance, benzo-DOTA, dibenzo-DOTA,(α,α′,α″,α′″)-tetramethyl-1,4,7,10-tetraazacyclotetradecane-1,4,7,10-tetraaceticacid (DOTMA); or1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N′″-tetraacetic acid (TETA);or corresponding compounds wherein one or more of the carboxylic groupsis replaced by a phosphonic and/or phosphinic group, including, forinstance, N,N′-bis-(pyridoxal-5-phosphate) ethylenediamine-N.N′-diaceticacid (DPDP); ethylenedinitrilo tetrakis(methylphosphonic) acid (EDTP),1,4,7,10-tetraazacyclotetradecane-1,4,7,10-tetra(methylenephosphonic)acid (DOTP), the phosphonoalkyl-polyaza macrocyclic compounds forinstance disclosed in U.S. Pat. No. 5,362,476 and U.S. Pat. No.5,409,689 and the linear phosphonoalkyl derivatives disclosed in U.S.Pat. No. 6,509,324; or macrocyclic chelants such as texaphirines,porphyrins, phthalocyanines.

Among the above, particularly preferred are: DTPA, DTPA-Glu, DTPA-Lys,DOTA and DOTA derivatives, such as those disclosed in Price E W andOrvig, Chem. Soc. Rev. 2014, 43:260 and the pyridil-DO3A disclosed inHermann et al, Dalton Trans., 2008, 3027-3047 or the multidentate ligandAAZTA and its derivatives described, i.e. in WO03/008394 andWO2013/135750.

Preferred paramagnetic metal elements for MRI are those having atomicnumber ranging from 20 to 31, 39, 42, 43, 44, 49 and from 57 to 83.

Even more preferred paramagnetic metal ions are selected from thefollowing: Fe(2⁺), Fe(3⁺), Cu(2⁺), Ni(2⁺), Rh(2⁺), Co(2⁺), Cr(3⁺),Gd(3⁺), Eu(3⁺), Dy(3⁺), Tb(3⁺), Pm(3⁺), Nd(3⁺), Tm(3⁺), Ce(3+), Y(3+),Ho(3+), Er(3+), La(3+), Yb(3+), Mn(3+), Mn(2+; Gd(3+) being the mostpreferred.

Nuclear Imaging (Radionuclide Imaging) and Radiotherapy

In another embodiment of the invention, the moiety to which the selectintargeting chimeric protein of the present invention is linked, is aradionuclide, for radioimaging (diagnostic) or radiotherapy (therapeuticapplication).

The main features of a radiometal chelating moiety relates to its use invivo at extremely diluted conditions, i.e. from nM to pM concentrations;however some of the most suitable matches between chelating moiety andradiometal are known and summarized in Price E W and Orvig C Chem. Soc.Rev, 2014, 43, 260.

For radioimaging, the targeting agent can be linked to a “radioimagingdetectable moiety” i.e. a moiety that is detectable by imagingtechniques such as scintigraphic imaging, Single Photon EmissionComputed Tomography (SPECT) or Positron Emission Tomography (PET).

Preferably, said radioimaging detectable moiety comprises a radionuclidechelated to a chelating agent which is usually bifunctional and whichcomprises the chelating moiety with metal complexing properties and afunctional group for attachment to the biomolecule, such as the Selectintargeting agent of the present invention or, alternatively, is directlylinked to the biomolecule (i.e. iodine).

Functional groups forming an amide, thiourea, urea, Schiff base orthioether bonds with amine or thiol groups on proteins may be preparedcarrying the chelating agent, labelled with a radionuclide detectable bythe said scintigraphic, SPECT or PET imaging techniques.

In any case, the most preferred chelating ligands are linear or morepreferably macrocyclic chelating ligands and are those discussed above,such as DTPA or, more preferably, DOTA which still represents a goldstandard for a number of isotopes including ¹¹¹In, ¹⁷⁷Lu, ^(86/90)Y,²²⁵Ac and ^(44/47)SC and which has been extensively used with ^(67/68)Ga, even though more recently replaced by the more stable NOTA and DOTAderivatives thereof.

Further suitable examples of chelating ligands for radionuclides may beselected from linear, macrocyclic, terpyridine, and N₃S, N₂S₂, N₂S₃,N₂S₄, N₃S₃ or N₄ chelators including, for instance, the ligandsdisclosed in U.S. Pat. No. 5,367,080, U.S. Pat. No. 5,364,613, U.S. Pat.No. 5,021,556, U.S. Pat. No. 5,075,099 and U.S. Pat. No. 5,886,142, andother chelating ligands known in the art including, but not limited to,6-Hydrazinopyridine-3-carboxylic acid (HYNIC), or1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N′″-tetraacetic acid (TETA);and bis-amino bis-thiol (BAT) chelators such as, for instance, thosedisclosed in U.S. Pat. No. 5,720,934, or phospho-derivatives ofpolyazamacrocyclic compounds, such as those described in WO2005/062828.

N₄ chelating ligands are also described, for instance, in U.S. Pat. No.5,608,110, U.S. Pat. No. 5,665,329, U.S. Pat. No. 5,656,254 and U.S.Pat. No. 5,688,487. Certain N₃S or N₂S₂ chelators are described, forinstance, in U.S. Pat. No. 5,659,041, U.S. Pat. No. 5,574,140, U.S. Pat.No. 5,780,006, U.S. Pat. No. 5,662,885 and U.S. Pat. No. 5,976,495. Thechelators may also include derivatives of the chelating ligandmercapto-acetyl-acetyl-glycyl-glycine (MAG3), which contains an N₃S andN₂S₂ system such as MAMA (monoamidemonoaminedithiols), DADS (N₂Sdiaminedithiols), CODADS, and the like. These ligand systems and avariety of others are described in Liu and Edwards, Chem Rev, 1999, 99,2235-2268 and references cited therein.

The chelating may also include complexes containing ligand atoms thatare not donated to the metal in a tetradentate array. These include theboronic acid adducts of technetium and rhenium dioximes, for instancedescribed in U.S. Pat. No. 5,183,653, U.S. Pat. No. 5,387,409 and U.S.Pat. No. 5,118,797.

In another embodiment, disulfide bonds of the fusion protein orpolypeptide of the invention are used as ligands for chelation of aradionuclide such as ^(99m)Tc. In this way, the peptide loop is expandedby the introduction of Tc (peptide-S—S-peptide changed topeptide-S—Tc—S-peptide).

Preferred radionuclides according to the present invention include, forinstance: ^(99m)Tc, ⁵¹Cr, ⁶⁷Ga, ⁶⁸Ga, ⁴⁷Sc, ¹⁶⁷Tm, ¹⁴¹Ce, ¹¹¹In, ¹¹³In,¹⁶⁸Yb, ¹⁷⁵Yb, ¹⁴⁰La, ⁹⁰Y, ⁸⁸Y, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁶⁵Dy, ¹⁶⁶Dy, ⁶¹Cu, ⁶²Cu,⁶⁴Cu, ⁶⁷Cu, ⁹⁷Ru, ¹⁰³Ru, ¹⁸⁶Re, ¹⁸⁸Re, ²⁰³Pb, ²¹¹Bi, ²¹²Bi, ²¹³Bi,²¹⁴Bi, ¹⁰⁵Rh, ¹⁰⁹Pd, ^(117m)Sn, ¹⁴⁹Pm, ¹⁶¹Tb, ¹⁷⁷Lu, ¹⁹⁸Au, ¹¹¹Ag,¹⁹⁹Au, ⁵¹Mn, ^(52m)Mn, ⁵²Fe, ⁶⁰Cu, ⁷²As, ^(94m)Tc, or ¹¹⁰In, ¹⁴²Pr,¹⁵⁹Gd.

The choice of the radionuclide will be based on the desired therapeuticor diagnostic application. For example, for therapeutic purposes (e.g.,to provide radiotherapy for primary tumors and metastasis), thepreferred radionuclides may include ⁶⁴Cu, ⁹⁰Y, ¹⁰⁵Rh, ¹¹¹In, ^(117m)Sn,¹⁴⁹Pm, ¹⁵³Sm, ¹⁶¹Tb, ¹⁶⁶Dy, ¹⁶⁶Ho, ¹⁷⁵Yb, ¹⁷⁷Lu, ^(186/188)Re, and¹⁹⁹Au, with ^(186/188)Re, ¹⁷⁷Lu and ⁹⁰Y being particularly preferred.For diagnostic purposes (e.g., to locate inflammation and to monitor itsdevelopment after therapy) the preferred radionuclides may include ⁶⁴Cu,⁶⁷Ga, ⁶⁸Ga, ^(99m)Tc, and ¹¹¹In. ^(99m)Tc is particularly preferred fordiagnostic applications because of its low cost, availability, imagingproperties and high specific activity. In particular, the nuclear andradioactive properties of ^(99m)Tc make this isotope an idealscintigraphic imaging agent. This isotope, in fact, has a single photonenergy of 140 keV and a radioactive half-life of about 6 hours, and isreadily available from a ⁹⁹Mo-^(99m)Tc generator.

Preferred metal radionuclides for use in PET imaging are positronemitting metal ions such as, for instance: ⁵¹Mn, ⁵²Fe, ⁶⁰Cu, ⁶⁸Ga, ⁷²As,^(94m)Tc or ¹¹⁰In.

Preferred chelating ligands are for ¹¹¹In and radioactive lanthanidessuch as, for instance, ¹⁷⁷Lu, ⁹⁰Y, ¹⁵³Sm, and ¹⁶⁶Ho or for ⁶⁷Ga, ⁶⁸Ga,⁶¹Cu, ⁶²Cu, ⁶⁴Cu or ⁶⁷Cu) selected from the group consisting of:

In particular, for metal entities including ¹¹¹In and radioactivelanthanides such as, for example ¹⁷⁷Lu, ⁹⁰Y, ¹⁵³Sm, and ¹⁶⁶Ho,particularly preferred are the following ligand residues:

where in the above formulae a) and b), R is alkyl, preferably methyl.

For radioactive ^(99m)Tc, ¹⁸⁶Re, ¹⁸⁸Re, particularly preferred are thefollowing chelating moieties from d) to l) below:

These and other metal chelating groups are for instance described inU.S. Pat. No. 5,608,110, U.S. Pat. No. 6,143,274, U.S. Pat. No.5,627,286, U.S. Pat. No. 5,662,885, U.S. Pat. No. 5,780,006 and U.S.Pat. No. 5,976,495. Additionally, the above chelating group of formulac) is described in U.S. Pat. No. 6,143,274; the chelating groups of theabove formulae h) and i) are described in U.S. Pat. No. 5,627,286 andU.S. Pat. No. 6,093,382; and the chelating group of formula I) isdescribed in U.S. Pat. No. 5,662,885, U.S. Pat. No. 5,780,006 and U.S.Pat. No. 5,976,495.

In the formulae h) and i), X is either CH₂ or O, Y is either C₁-C₁₀branched or unbranched alkyl; Y is aryl, aryloxy, arylamino,arylaminoacyl; Y is arylkyl where the alkyl group or groups attached tothe aryl moiety are C₁-C₁₀ branched or unbranched alkyl groups, C₁-C₁₀branched or unbranched hydroxy or polyhydroxyalkyl groups orpolyalkoxyalkyl or polyhydroxy-polyalkoxyalkyl groups, J is >C(═O),—OC(═O)—, —SO₂—, >NC(═O)—, >NC(═S)—, —N(Y)—, —NC(═NCH₃)—, —NC(═NH)—,—N═N—, homopolyamides or heteropolyamines derived from synthetic ornaturally occurring amino acids; all where n is 1-100. Folatederivatives of these structures are described, for example, in U.S. Pat.No. 6,093,382.

More preferred for scintigraphy, are radioimaging contrast agentscomprising one of the above ligand residues from a) to l) above labelledwith ^(99m)Tc as imaging detectable moiety.

PET Imaging with Labelled Sugars

In a still further embodiment of the invention, the fusion protein islinked to a labelled sugar moiety for use in PET Imaging.

Preferably, the sugar moiety is labelled by halogenation withradionuclides such as, for instance: ¹²⁴I, ¹²⁵I, ¹³¹I, ¹²³I, ⁷⁷Br, ⁷⁶Brand ¹⁸F; ¹⁸F being as particularly preferred.

Optical Imaging

In some embodiments, an optical imaging agent is conjugated to thechimeric protein of the invention. Among optical imaging agents,fluorescent dyes for imaging applications in vivo, ex vivo and in vitroare well known by the skilled artisan and a wide range of fluorochromeswhich are optimal for the in vivo fluorescence imaging have beendeveloped and are also commercially available.

These reagents maximise to different extents, the depth of tissuepenetration, the light scattering and fluorescence emission propertiesof fluorescent chromophores, to provide optimal signal-to-backgroundratios. In general, light absorption and scattering decrease withincreasing wavelength; below about 700 nm, these effects result inshallow penetration depths of few millimeters, while above 900 nm waterabsorption can interfere with signal-to-background ratio. Thereforefluorochromes with excitation/emission in the near infrared (NIR) region(700-900 nm) have been mostly exploited up to now for in vivo imaging insmall animals and, potentially, in humans.

Among these the most used are: Indocyanin Green, cyanine derivativesCy3, Cy3.5, Cy5 and Cy5.5, Cy7 (cyanine dyes and derivatives are madeavailable, i.e. by GE Healthcare), LS-287, LS-288, IRDye®800CW, IR-820,IR®-806, IR-786, IRDye® 800RS, IRDye®750, IRDye®650 (IRDye®s are madeavailable from Li-Cor Bioscience), Alexa Fluor®647, Alexa Fluor®350,Alexa Fluor®405, Alexa Fluor®430, Alexa Fluor®488, Alexa Fluor®514,Alexa Fluor®532, Alexa Fluor®546, Alexa Fluor®568, Alexa Fluor®594,Alexa Fluor®680, Alexa Fluor®750 (Alexa Fluor® dyes are made available,i.e. from Invitrogen), combination thereof and others, whose chemicalstructures have been reported for example in WO2014/191467. Thestructure of most of the compounds for image-guided surgery and theircommercial availability has been described, i.e. in Gibbs S. L. QuantImaging Med Surg 2012, 2(3): 177-187. Particularly preferred are cyaninedyes and their chemical derivatives developed for NIR imaging, such as:Cy5.5, IRDye®800CW, IRDye® 800RS and IRDye®750.

Uses

The above described targeted diagnostic agents are particularly usefulfor imaging in vivo and ex vivo. The chimeric targeting protein of theinvention can further be used for therapeutic purposes, which includeany method for the treatment of a disease in a patient where thechimeric targeting protein of the invention is used, optionally inassociation with an imaging agent, to deliver ex-vivo and/or in vivo, atherapeutic compound, i.e. a molecule which is capable of exerting or isresponsible to exert a biological effect, to selectin expressing cell,tissue or organ.

Typically, this use involve the conjugation of the chimeric protein ofthe invention with an agent/moiety/molecule endowed with a biologicalactivity, such as a cytokine, cytostatic agent (such as doxorubicin,methotrexate, cisplatin, vinblastin, vincristin, etc.) toxin,anti-inflammatory agent, immunomodulator such as a cytokine inhibitor,antiaggregant, corticosteroid, monoclonal antibody, growth factor andthe above described radiotherapic agents comprising metal chelatingmoieties carrying a radionuclide, and is effected to target thebiologically active moiety to the selectin expressing tissue/cell/organ,where an inflammation is observed or detected.

The pathological inflammatory condition, either for diagnostic and/ortherapeutic purposes, should be characterized by selectin expressionlevels above physiological; the selectin is preferably E-selectin and/orP-selectin, more preferably P-selectin. In particular the imaging agentsof the invention are useful to detect inflammatory conditions of thevascular endothelium such as the ones listed below.

More preferably, the pathological inflammatory condition is selectedamong the following, characterized for selectin expression levels abovephysiological: Acute Coronary Syndrome (ACS), Inflammatory Bowel Disease(IBD), Ulcerative colitis, Crohn's disease, neo-angiogenesis associatedwith tumors, rheumatoid arthritis, ischemia reperfusion injury, graftrejection or, more in general, of any organ or tissue expressingP-selectin and/or E-selectin above physiological levels.

More preferably, the chimeric protein of the invention is a usefultargeting agent for IBD, ACS, tumour detection and graft rejection.

Furthermore, the targeted imaging agents according to the invention isemployed as an efficient diagnostic tool during the (therapeutic)treatment of a patient suffering from an inflammatory disease orpathology, where “during” includes any time before the beginning of thetreatment, in the course of said treatment and/or at the end of saidtreatment, to monitor and evaluate it. For instance the targeted imagingagents of the invention can advantageously be employed in the monitoringand/or follow-up of an anti-inflammatory treatment (e.g. of any of theabove cited diseases or pathologies), e.g. to determine or evaluate theeffects of the administration of an anti-inflammatory orinflammatory-inhibitor drug on the disease or pathology.

For example, in IBD, the targeted imaging agents of the invention can beused to follow-up the response to the therapeutic treatment with, i.e.mesalamine, corticosteroids, methotrexate or infliximab and to stratifypatients according to their response to the therapeutic treatment or tomonitor the remission maintenance therapy. Preferably, the imagingtechnique is based on the chimeric soluble protein-targeted microbubblesfor ultrasound detection.

In a preferred embodiment, during a treatment a region of interest ofthe patient is subjected to the imaging detection system of choice uponadministration of the targeted imaging agents of the invention, forinstance at regular time intervals, at a predetermined time intervalafter each drug administration or therapeutic intervention and/or aftera selected number of drug administrations or treatments; a final imagingof the region of interest is then preferably performed at the end orconclusion of the treatment.

The targeted imaging agents of the invention can be further used inultrasound-related techniques, i.e. in therapeutic-associated imaging,in which they are advantageously associated with a controlled localizeddestruction of the gas-filled microvesicles, e.g. by means of ultrasoundwaves at high acoustic pressure (typically higher than the one generallyemployed in non-destructive diagnostic imaging methods). This controlleddestruction may be used, for instance, for the treatment of blood clots(a technique also known as sonothrombolysis), optionally in combinationwith the release of a suitable therapeutic compound associated with thecontrast agent. Alternatively, said therapeutic-associated imaging mayinclude the delivery of a therapeutic agent into cells, as a result of atransient membrane permeabilization at the cellular level induced by thelocalized burst or activation of the microvesicles. This technique canbe used, for instance, for an effective delivery of genetic materialinto the cells; alternatively, a drug can be locally delivered,optionally in combination with genetic material, thus allowing acombined pharmaceutical/genetic therapy of the patient (e.g. in case oftumor treatment). The therapeutic agent can be associated with thegas-filled microvesicle according to conventional methods, or can beadministered as a separate compound of the composition. In addition, thetargeting agent could be used to facilitate the delivery of therapeuticagent into the brain tissue by transient opening of the Blood BrainBarrier following exposure to ultrasound.

Typically, an effective amount of the targeted diagnostic agent isadministered (e.g. by injection) to a patient in need thereof and thebody part or tissue of the patient to be imaged or treated (“region ofinterest”) is subjected to the desired imaging method. Preferably, thecontrast agent is administered intravenously. The term patient includesany subject (human or animal) undergoing the administration of thecontrast agent, either for diagnostic/therapeutic purposes or forexperimental purposes (including, for instance, use of a contrast agentin laboratory animals, e.g. to follow an experimental therapeutictreatment).

According to a preferred embodiment, an effective amount of targetedmicrovesicles is administered to a patient, typically by injection of asuspension thereof. The imaging of the region of interest will thus beenhanced by the presence of the microvesicles bound to the target in theregion of interest.

A variety of imaging techniques may be employed in ultrasoundapplications, for example including fundamental and non-linear (e.g.harmonic) B-mode imaging, pulse or phase inversion imaging andfundamental and non-linear Doppler imaging; if desired three- orfour-dimensional imaging techniques may be used. Furthermore, diagnostictechniques entailing the destruction of gas-filled microvesicles (e.g.by means of ultrasound waves at high acoustical pressure) which arehighly sensitive detection methods are also contemplated.

Microvesicles according to the invention can typically be administeredin a concentration of from about 0.01 to about 5.0 μl of gas (entrappedinside the microvesicles) per kg of patient, depending e.g. on theirrespective composition, the tissue or organ to be imaged and/or thechosen imaging technique. This general concentration range can of coursevary depending from specific imaging applications, e.g. when signals canbe observed at very low doses such as in color Doppler or power pulseinversion. Possible other diagnostic imaging applications includescintigraphy, optical imaging, photo-acoustic imaging, magneticresonance imaging and X-ray imaging, including X-ray phase contrastimaging.

Ultrasound imaging methods can be also conveniently used in associationwith MRI as mentioned above for combined- (or fusion-) imaging methodsto achieve better mapping of the affected lesion.

Pharmaceutical Compositions

The invention further comprises pharmaceutical compositions comprisingthe above disclosed chimeric protein, either conjugated or modifiedaccording to the uses envisaged, which may be administered topically, orparenterally including intranasal, subcutaneous, intramuscular,intravenous, intra-arterial, intraarticular, or intralesionaladministration. Ordinarily, intravenous (i.v.), intraarterial,intraarticular, intracardiac administration is preferred.

The molecules of the present invention, as the active ingredient, aredissolved, dispersed or admixed in a diluent or excipient that ispharmaceutically acceptable and compatible with the active ingredient,as well known in the art. Suitable excipients are, for example, water,saline, phosphate buffered saline (PBS), dextrose, glycerol, ethanol, orthe like and combinations thereof. Other suitable carriers are wellknown to those skilled in the art. In addition, if desired, thecomposition can contain minor amounts of auxiliary substances such aswetting or emulsifying agents, stabilizing and/or pH buffering agents.

Pharmaceutical compositions according to the present invention may bemanufactured by means, i.e. of conventional mixing, dissolving,granulating, grinding, pulverizing, dragee-making, levigating,emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the presentinvention thus, may be formulated using one or more physiologicallyacceptable carriers comprising excipients and auxiliaries, whichfacilitate processing of the active compounds into preparations whichcan be used pharmaceutically. Proper formulation is dependent upon theroute of administration chosen.

For injection, the compounds of the invention may be formulated inaqueous solutions, preferably in physiologically compatible buffers suchas Hank's solution, Ringer's solution, or physiological saline bufferfurther comprising suitable excipients or stabilizing compounds.

Oral administration can be achieved by liquid or solid compositions.Among the latter dragee cores are provided with suitable coatings. Forthis purpose, concentrated sugar solutions may be used which mayoptionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopolgel, polyethylene glycol, titanium dioxide, lacquer solutions andsuitable organic solvents or solvent mixtures. Dyestuffs or pigments maybe added to the tablets or dragee coatings for identification or tocharacterize different combinations of active compound doses.

Orally administered solid compositions include push-fit capsules made ofgelatin as well as soft, sealed capsules made of gelatin and aplasticizer, such as glycerol or sorbitol. The push-fit capsules maycontain the active ingredients in admixture with filler such as lactose,binders such as starches, lubricants such as talc or magnesium stearateand, optionally, stabilizers. In soft capsules, the active compounds maybe dissolved or suspended in suitable liquids, such as fatty oils,liquid paraffin, or liquid polyethylene glycols. In addition,stabilizers may be added. All formulations for oral administrationshould be in dosages suitable for the chosen route of administration.For buccal administration, the compositions may take the form of tabletsor lozenges formulated in conventional manner.

In one embodiment according to the present invention, the peptides areadministered orally (e.g. as a syrup, capsule, or tablet). In certainembodiments, peptide delivery can be enhanced by the use of protectiveexcipients. This is typically accomplished either by complexing thepeptide with a composition to render it resistant to acidic andenzymatic hydrolysis or by packaging the peptide in an appropriatelyresistant carrier such as a liposome. Means of protecting peptides fororal delivery are well known in the art.

Compressed tablets may be prepared by compressing in a suitable machinethe active peptide(s) in a free-flowing form such as a powder orgranules, optionally mixed with a binder, (e.g. povidone, gelatin,hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative,disintegrant (e.g. sodium starch glycollate, cross-linked povidone,cross-linked sodium carboxymethyl cellulose), surface active ordispersing agent. Molded tablets may be made by molding in a suitablemachine a mixture of the powdered peptide(s) moistened with an inertliquid diluent. The tablets may optionally be coated or scored and maybe formulated so as to provide slow or controlled release of the activeingredient therein using, for example, hydroxypropylmethyl cellulose invarying proportions to provide the desired release profile.

Syrup may be made by adding the active peptide(s) to a concentrated,aqueous solution of a sugar, for example, sucrose, to which may also beadded any necessary ingredients. Such accessory ingredients may includeflavorings, an agent to retard crystallization of the sugar or an agentto increase the solubility of any other ingredients, such as apolyhydric alcohol, for example, glycerol or sorbitol.

For administration by inhalation, the variants for use according to thepresent invention are conveniently delivered in the form of an aerosolspray presentation from a pressurized pack or a nebulizer with the useof a suitable propellant, e.g., dichlorodifluoromethane,trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. Inthe case of a pressurized aerosol, the dosage unit may be determined byproviding a valve to deliver a metered amount. Capsules and cartridgesof, e.g., gelatin for use in an inhaler or insufflators may beformulated containing a powder mix of the peptide and a suitable powderbase such as lactose or starch.

Pharmaceutical compositions for parenteral administration includeaqueous solutions of the active ingredients in water-soluble form.Additionally, suspensions of the active compounds may be prepared asappropriate oily injection suspensions. Suitable natural or syntheticcarriers are well known in the art. The suspension may also containsuitable stabilizers or agents, which increase the solubility of thecompounds or the stability of the chimeric protein or the conjugatedgroup, to allow for the preparation of concentrated solutions.Alternatively, the active ingredient may be in powder form forreconstitution with a suitable vehicle, e.g., sterile, pyrogen-freewater, before use.

The compounds of the present invention may also be formulated in rectalcompositions such as suppositories or retention enemas, using, e.g.,conventional suppository bases such as cocoa butter or other glycerides.

Elevated serum half-life can be maintained by the use ofsustained-release protein or lipids as “packaging” systems. Suchsustained release systems are well known to those of skill in the artand may comprise formulation of the chimeric protein as such or in aconjugated form into nanospheres, nanovesicles or liposomes.

The foregoing formulations and administration methods are intended to beillustrative and not limiting. It will be appreciated that, using theteaching provided herein, other suitable formulations and modes ofadministration can be readily devised.

Pharmaceutical compositions suitable for use in context of the presentinvention include compositions wherein the active ingredients arecontained in an amount effective to achieve the intended purpose. Morespecifically, a therapeutically effective amount means an amount of acompound effective to prevent, delay, alleviate or ameliorate symptomsof a disease of the subject being treated.

Determination of a therapeutically effective amount is well within thecapability of those skilled in the art according, i.e. to Goodman &Gilman, ^(9th) ed, J G Hardman, A. Gilman, L E Limbird, Chapter I“Pharmacokinetics”, pp 3-27.

Accordingly, the present invention further comprises methods foradministration of the chimeric protein above disclosed either as such orpreferably as a conjugate to persons in need thereof, for therapeuticor, preferably, diagnostic purposes.

For diagnostic purposes the pharmaceutical compositions of the inventionmay be pre-administered in a suitable dosage, depending on theadministration route and sensibility of the diagnostic method, and thenimaging carried out by the most suited technique.

EXPERIMENTAL PART Example 1: Preparation and Expression of FlaggedRecombinant Fusion Proteins

A number of DNA constructs were prepared:

PSGL Variant 1: the sequence encodes for aminoacids 1-47 of the maturePSGL-1 protein, the IgG₁ hinge region, the Leucine Zipper domain of NRL,a glycine (G₄SG₄) spacer and a FLAG sequence for affinity recognition.The mouse IgH signal peptide was used for secretion. The Variant 1chimeric protein has amino acid sequence SEQ ID NO:2.

The PSGL Variant 2, which encodes for amino acids 1-47 of the maturePSGL-1 protein, a IgG1 hinge region, a IgG1CH3 region with K->A sequencereplacements. The mouse IgH signal peptide was used for secretion. AFLAG Sequence (SEQ ID NO:35) at the C-term, was used for purificationpurposes. The chimeric protein has SEQ ID NO:4.

PSGL Variant 3: encoding for amino acids 1-47 of the mature PSGL-1protein, covalently linked to the IgG1 hinge region, to region 275-290of the mature PSGL-1 protein and a FLAG Sequence (SEQ ID NO:35) at theC-term, used for identification and purification purposes. The mouse IgHsignal peptide was used for secretion. The chimeric protein has SEQ IDNO:6.

The PSGL Variant 4 encodes for amino acids 1-47 of the mature PSGL-1protein, covalently linked to the IgG1 Hinge region and aa 1-15 of thehuman IgG1 Fc region. The mouse IgH signal peptide was used forsecretion. A FLAG Sequence (SEQ ID NO:35) at the C-term, was used forpurification purposes. The chimeric protein has SEQ ID NO:8.

The PSGL Variant 5 encodes for amino acids 1-88 of the PSGL-1 protein(according to GI:2498904) with the endogenous signal and propeptidesequence covalently linked to the IgG1 Hinge region and aa 1-15 of thehuman IgG1 Fc region. A FLAG Sequence (SEQ ID NO:35) at the C-term foraffinity recognition, was used for purification purposes. The chimericprotein has SEQ ID NO:10.

Small-Scale Transient Transfection

CHO-S, a suspension-adapted Chinese hamster ovary cell line (Freedom™CHO-S™ Kit, GIBCO ThermoFisher Scientific) was cultured according to theManufacturer's instruction (July 2015) in a humidified 5% CO₂ incubatorat 37° C. in chemically defined media CD-CHO (Invitrogen, CarlsbadCalif., Catalog#12490-025, Lot#1149771) supplemented with L-glutamine(Cellgro, Catalog#61-030-RO, Lot#61030158). No serum or otheranimal-derived products were used in culturing the CHO-S cells. 24 hoursbefore transfection cells were seeded in shake flask, and grown usingserum-free chemically defined media. Variants 1-5 expression constructs(250 μg of each plasmid) were transiently transfected into 0.05 litersuspension CHO cells by electroporation. Briefly: 250×10⁶ CHO cells weretransfected using a Maxcyte Electroporator with 50% EP buffer and QC400cuvette. Cells were grown using serum free media for seven days prior toharvest.

A Western blot performed at harvest demonstrated relative expression ofPSGL-1 variants. Western blot analysis specific for the FLAG tag onconditioned media in non-reducing conditions confirmed proteindimerization. Variant 1 in the conditioned media showed under reducingconditions the expected molecular weight of ˜22 kDa (FIG. 1, Lane 2). Itcorrectly formed a dimer under non reducing conditions (FIG. 1, Lane 7).High molecular bands found in bands 1-5 are most likely molecules boundnon-specifically to the anti-FLAG antibody (Anti-FLAG antibody,monoclonal mouse IgG1, Sigma-Aldrich, catalog # F1804).

In the case of lane 3 (Variant 2), the lower molecular weight bandsmight be a degradation product.

The western blot on the conditioned medium was carried out with anantibody which recognizes the Flag epitope placed at the C-terminus ofall variants and is therefore indicative of the relative quantity of thedifferent constructs of the chimeric protein secreted into the medium.

Purification of the FLAGGED Variants

Purification was carried out by ion exchange and anti-FLAG affinitypurification. For each of the five variants, following clarification by0.2 μM filtration the conditioned media was adjusted to pH 6 by theaddition of 1 M HCl, and the volume was doubled with distilled water.The CM was then loaded onto a 1 mL anion exchange chromatography column(Q column, GE) and eluted in 20 mM Tris pH 7.5, 1 M HCl. The elutionfraction was applied to 0.5 mL of anti-FLAG affinity M2 resin and rockedat room temperature for 5 hours. The resin was washed with 10 mL of Trisbuffered saline. The protein was eluted with five column volumes of 100μg/mL FLAG peptide in Tris buffered saline. For PSGL Variant 1, theflow-through was reincubated with anti-FLAG M2 resin overnight at 4° C.,and elution was achieved using 0.25% acetic acid pH 3.5.

The Silver staining SDS-PAGE and OD₂₂₀ analysis of the purified PSGLVariants 1-5 suggests that Variant 1 has the highest purity andexpression level among five constructs.

Protein concentration at OD₂₂₀, calculated by creating a standard curvewith serial dilution of Bovine serum albumin and fitting the data fromPSGL variants to that curve is given below in Table 3.

TABLE 3 recovery of protein Variants 1-5 after ion exchange and affinitypurification Variant Variant Variant Variant Variant 1 2 3 4 5 Amount(mg) 0.41 0.07 0.02 0.02 0.03

Among the five constructs, PSGL Variant 1 had the better yields: highestexpression level and resulting purity by at least one log compared tothe other Variants. Both western blot and silver staining SDS-PAGE underreducing and non-reducing conditions suggested that PSGL Variant 1dimerized correctly.

Example 2: Expression and Purification of Variant 1A (without FLAG)

Stable CHO-S cells stable transformants, co-expressing the DNA sequenceencoding the core 2 beta-1,6-N-acetylglucosaminyltransferase (C2GnT-M),the FTVII (fucosyl-transferase VII) (Fugang Li et al. J. Biol. Chem,1996, 271:3255-3264) and the chimeric protein encompassing aa 1-118 ofSEQ ID NO:1 without FLAG sequence, was then produced according to theFreedom™ CHO-S™ Kit Manual (Cat.N A13696-01 Lifescience ThermofisherScientific, July 2015).

CHO-S clones were allowed to grow for at least 7 days, usually up to 14days, using OptiCHO™ medium (other serum-free chemically defined mediawere successfully used, e.g., ActiCHO™, CD FortiCHO™, and the likes) andin the absence of selection pressure. Glutamine (or the analogueGlutMax) was supplemented at 1-10 mM, preferably 4-8 mM.

100 mL of the supernatant from a pool of 6 stable CHO clones wascollected, filtered on 0.2 μm PES membrane and loaded onto a stronganion exchange Capto Q column (GE 17-5316-02, 1.6×6 cm, 12 mL)previously equilibrated with 20 mM TRIS-HCl pH 7.5.

The bound proteins were eluted with a linear gradient of up to 1 M NaClover 8 column volumes. The eluted fractions that contained the targetprotein, as shown by SDS-PAGE analysis were used for a second Phenylhydrophobic interaction chromatography purification step.

The column was washed with 1 M NaOH, then equilibrated with and storedat 4° C. in 20% EtOH.

NaCl was dissolved in the pooled fractions to a concentration of 4 M.This pool was then loaded on 1 mL HIC column (HiTrap Phenyl HP™, GEHealthcare Life Sciences, Catalog #17-1351-01) previously equilibratedwith 20 mM TRIS-HCl pH 7.5, 4 M NaCl, according to the manufacturer'sinstructions for a hydrophobic interaction chromatography. Elution wasachieved by linearly decreasing the sodium chloride concentration tozero in 10 column volumes. Fractions containing the target protein asshown by SDS-PAGE analysis were pooled together for a third sizeexclusion chromatography (SEC) step. The SEC column (HiLoad 16/600Superdex 200™ pg, GE Healthcare Life Sciences, Catalog #28-9893-35) waspre-equilibrated with 20 mM Tris-HCl pH 7.5, 150 mM NaCl, which was usedas the mobile phase. Fractions containing the chimeric PSGL Variant 1 asshown by SDS-PAGE analysis were pooled and concentrated (Amicon UltraCentrifugal Filter Unit, EMD Millipore).

As a more sensitive alternative to SDS-PAGE, Western Blot analysis wasperformed with Phast-System (GE) as described in the instruction manual.Nitrocellulose membrane was saturated with PBS+1% BSA (1 h at roomtemperature). The membrane was incubated 1 h at room temperature withPBS+0.5% Triton X-100+1% BSA containing an anti-P-Selectin GlycoproteinLigand-1 antibody 1:1000 (anti-P-Selectin Glycoprotein Ligand-1Antibody, clone KPL-1, EMD Millipore, cod. MAB4092).

After 3 washes with PBS+0.5% Triton X-100 the membrane was incubatedwith anti-mouse IgG-HRP as secondary antibody.

After 3 washings, the HRP signal was developed with ECL, showingpositive anti-PSGL-1 antibody recognition.

The chimeric PSGL Variant 1A, from different subclones appeared as asingle band at approximately 60 kDa, which shifted at about 30 kDa underreducing conditions, as expected. Neither additional bands nordegradation products were visible in Coomassie stained SDS-PAGE gels ofpurified product.

One clone was selected for further sub-cloning, medium scale growth andpurification on a 2 L culture medium scale.

Example 3: Characterization of Purified Variant 1A

The PSGL Variant 1A recombinant protein, is highly heterogeneous due todifferent post-translational modifications, including sulfation and bothN- and 0-glycosylation. For its full characterization and correctquantification a set of analytical methods including UPLC, MS andpeptide mapping procedures with specific enzymes was used. PSGL Variant1A structural features, essential to its bioactivity, were alsocarefully monitored.

3.1. Uplc-Uv

Reversed phase chromatography was used to determine the target proteincontent and to quantitate possible impurities or degradation products.For reverse phase chromatography experiments, an Acquity UPLC BEH300column (2.1×100 mm, 1.7 μm) was used at 50° C. in gradient mode. Themobile phases were (A) 0.1% TFA in water and (B) 0.1% TFA inacetonitrile. UV detection was performed at 216 nm. The use of UPLCtechnology combined with a dedicated sub 2 μm column allowed improvedresolution, higher sensitivity, excellent peak shape and significantreduction in analysis times. The UPLC-UV method showed that the PSGLVariant 1A purity achieved by the purification process was higher than90%.

3.2. SEC-UV

Size Exclusion Chromatography (SEC), also called Gel PermeationChromatography (GPC), coupled to UV detection, which allows theseparation of proteins on the basis of their effective size or shape(hydrodynamic radius), was used. In this case, the method was used tomeasure possible aggregates and other size Variants. For size exclusionchromatography experiments, TSK gel super SW mAb HTP 4.6×150 mm (Tosoh),4 μm column was used at 30° C. in isocratic mode. The mobile phase was50 mM NaH₂PO₄, 50 mM Na₂HPO₄, 100 mM Na2SO₄ and UV detection wasperformed at 216 nm. The use of UPLC instrumentation optimized to reduceextra-column band broadening allowed high column efficiency andincreased sensitivity. The SEC-UV method was applied for the analysis ofPSGL variant A-1: no aggregation was observed.

3.3. Sialic Acid Content

Sialylation is well known as a critical feature to biopharmaceuticalproducts' bioavailability, stability, metabolism and immunogenicity. Tothis aim, a HPLC MS method was developed for the sialic aciddetermination of the chimeric protein Variant 1A.

The analysis was based on the combination of chemical hydrolysis methodcoupled with a derivatization-free liquid chromatography interfaced withelectrospray ionization tandem mass spectrometry (LC-MS/MS). Sialic acid(N-Acetyl neuraminic acid NANA) was firstly released from PSGL Variant1A by acid hydrolysis under mild acidic conditions. Once the sialic acidwas released, its quantitation was carried out thanks to the use ofLC-MS/MS method. The sialic acid amount was determined by comparing theresponse in the sample to a reference standard calibration curve. Inexperiments carried out with protein purified from other CHO subclones,sialylation was found to be typically comprised from 9.6 to 17.9% w/w.

3.4. MALDI-TOF-MS

Matrix Assisted Laser Desorption Ionization-Time Of Flight massspectrometry (MALDI-TOF-MS), analyses were also performed to determinethe PSGL Variant 1A molecular weight. This technique involves mixing thesample with a matrix, which is then coated onto a plate or probe, andsubjected to a collimated focused laser beam, causing ionization anddesorption. MALDI has the advantage of producing large mass ions, withhigh sensitivity and little fragmentation. MALDI-TOF experiments wereperformed on PSGL Variant 1A, under intact and reduced forms.

As determined by MALDI experiments, the mean molecular weight of PSGLVariant 1A was measured at around 35.4 kDa. Reduction with DTT led to a2-fold decrease of the PSGL Variant 1A mass, indicating the dimericnature of the purified protein.

3.5. Peptide Mapping (Enzymatic Digestion)

Peptide mapping (PMAP) was used to elucidate the post-translationalmodifications (PTMs) of the chimeric glycoprotein, including sulfationand N- and O-glycosylation.

To this aim, both Chymotrypsin and Asp-N were applied for proteindigestion, followed by LC-MS Liquid Chromatography-Mass Spectrometry.

3.5.1. Fragmentation with Chymotrypsin

Chymotrypsin fragmentation was performed following the protocol providedby the manufacturer (Chymotrypsin Endoproteinase MS Grade, Cat.N. 90056,Thermo Scientific). One vial of dry chymotrypsin was reconstituted in 25μL of HCl 0.1 M and stored at −18° C. before use as 2 μL aliquots in 500μL eppendorf tubes. To prepare digestion buffer, consisting in 100 mMTris-HCl pH (8, 10 mM CaCl₂, 3.03 g of Tris Base (M 121.4 g/mol) and 368mg CaCl₂ (M 147.02 g/mol) were dissolved in water. The pH was adjustedto 8.0 using 1.2 M HCl and the volume was completed to 250 mL.

Fifty (50) μL of a PSGL-1 Variant 1A stock solution (0.5-1.0 mg/mL) wereadded to 2 μL of chymotrypsin and 48 μL of digestion buffer. Thesolution was incubated for 18 hours at 37° C. before injection in LC-MS.

3.5.2. Fragmentation with Endoproteinase Asp-N

Endoproteinase Asp-N fragmentation was performed following the protocolprovided by the manufacturer (Asp N sequencing grade Roche, Cat. N.11054589001). One vial of dry Asp-N was reconstituted in 50 μL of waterand stored at −18° C. before use as 5 μL aliquots in 500 μL Eppendorftubes. To prepare digestion buffer, consisting in 50 mM SodiumPhosphate, 1.5 g of Na₂HPO₄ (M 119.98 g/mol) was dissolved in water. ThepH was adjusted to 8.0 using 1 M NaOH and the volume was completed to250 mL.

Ten (10) μL of a PSGL-1 Variant 1A stock solution (0.5-1.0 mg/mL) wereadded to 5 μL of chymotrypsin and 35 μL of digestion buffer. Thesolution was incubated for 18 hours at 37° C. before injection in LC-MS.

Similar LC-MS analyses were used for the characterization of Asp-N andchymotrypsin digests. These experiments were performed using a WatersAcquity® UPLC system consisting of a temperature controlled samplemanager, a binary solvent manager and a heated column compartment. Thecolumn outlet was connected directly to the mass spectrometer. Theanalytical column was a Poroshell® 120 EC-C18 2.1×150 mm i.d., particlesize 2.7 μm from Agilent® at 40° C. The elution of the compounds fromthe column was carried out in the gradient mode using a mobile phaseconsisting of ultrapure water with 0.1% TFA and acetonitrile with 0.1%of TFA. The flow rate and injection volume were set at 0.3 mL/min and 10μL, respectively. Detection was performed on a Waters Xevo TQ-S tandemquadrupole mass spectrometer equipped with electrospray ionizationsource in the positive and negative ionization mode according tocompound. Nitrogen and argon were used as nebulizing and collisiongases, respectively. Analyses were performed in the scan mode. Dataacquisition and processing were performed with the help of MassLynxsoftware package.

All the above assays allowed the following conclusions:

-   -   the N-term structure of the PSGL-1 Variant 1A glycoprotein is        dominated by the pyroglutamic form pQATEYEYL.    -   the dimeric character of the PSGL Variant 1A was confirmed by        the presence of (M+2H)⁺²=728.5 attributed to the (⁵⁰TCPPCPL⁵⁶)₂        sequence. Ions corresponding to the monomeric form of this        peptide were not detected, suggesting that PSGL Variant 1A is        entirely in the dimeric form.    -   the structure of the O-glycan residues on Thr¹⁶ was confirmed:        in fact, the expected Sialyl-Lewis-X motif, a Core 2 structure        comprising N-Acetylgalactosamine, N-Acetylglucosamine,        galactose, fucose and sialic acid was identified.    -   sulfation of Tyrosines 5, 7 and 10 was also demonstrated by mass        spectrometry in the negative scan mode.        Most of the post-translation modifications (PTM) have been        reported in SEQ ID NO:38.

Example 4: Affinity Binding on P-Selectin by Surface Plasmon Resonance(SPR)

The experiments were carried out with purified protein Fr1 as describedin Example 2 of WO2012/020030 and Variant 1A as described in Example 2above. The binding strength of PSGL Variant 1A was evaluated by SurfacePlasmon Resonance (SPR) using a Biacore X100 from GE HealthcareBio-Sciences AB (General Electric, Piscataway, N.J.). The SPR technologyallows monitoring the process of binding between biomolecules in realtime and without labels. While P-selectin (target ligand) was attachedto a sensor chip surface, the proteins of interest flowed in solutionover the surface using a microfluidic system to ensure reproduciblesample delivery and low sample consumption. SPR detects binding eventsas changes in mass at the chip surface. As a result, a sensogram isgenerated by plotting the SPR response against time.

Firstly, biotinylation of P-selectin/Fc (R&D Systems Europe Ltd) wasperformed in house. Then, immobilization of P-selectin/Fc on the workingsensor (Fc2) of SA Chip (Streptavidin chip, GE Healthcare Bio-Sciences)was carried out as follows: One volume of the 10×HBS-N buffer (GEHealthcare Bio-Sciences AB) (50 mL) was diluted with 9 volumes ofMilli-Q water (450 mL). Five hundred microliters of CaCl₂ 1.5 M (Fluka),pH about 5.6 were added to the diluted buffer (1.5 mM final) andfiltered through 0.2 μm PES filter. The running buffer was prepared with48.75 mL of HBS—N, CaCl₂ 1.5 mM buffer and 1.250 mL of surfactant P20(GE Healthcare Bio-Sciences AB) in a 50 mL Falcon tube. HBS—N buffer andCaCl₂ 1.5 mM not immediately used were stored at +4° C.

Each sample to test was diluted in running buffer to achieve theindicated concentration of 125 nM. A manual run was started on thereference sensor (Fc1) and Fc2 with a flow rate of 30 μL/min. Referencesubtraction 2-1 was selected. As soon as the base line was stable,analyte was injected for 30 sec. or longer if binding equilibrium wasnot reached. To directly compare binding of different analytes ordifferent concentrations of the same analyte, it was necessary toprogram the same cycle parameters for each sample, for example:

-   -   Wait 120 sec.    -   Injection 30 sec.    -   Wait 300 sec.

When the manual run was finished, the Biacore X100 Evaluation softwareversion 1.0 was opened, to create an overlay of each cycle.

Based on SPR experiments the binding affinity towards P-selectin wasmeasured and the binding strength of the chimeric proteins to the targetfound to be equivalent or better than the Fr1 binding. FIG. 2 shows theresult of the Biacore run, where the chimeric protein of the presentinvention (hatched line) showed an improved binding to the P-selectinligand with respect to Fr.1.

SPR was also used for Variant 1A titration in the cell supernatant,according to the method described in Chou T-H. et al. Cytokine 51, 2010,107-111. The sensor chip was overlayed with streptavidin and a mouseα-PSGL-1 antibody (KPL-1, Abcam, cat. N. ab78188) biotinylated atBracco, used to quantitate Variant 1A in the supernatant.

Example 5: Preparation of Variant 1A-SMCC for Phospholipid Conjugation

The process was carried out according to example 9 of WO2012/020030.

Briefly, Variant 1 (65 nmoles) from example 2 was dissolved in 1 mL ofPhosphate buffer 0.2 M pH 7.5 with 1 mM EDTA. A solution of Sulfo-SMCC(Sulfo-SMCC: sulfosuccinimidyl4-[N-maleimidomethyl]cyclohexane-1-carboxylate) (Pierce) (55 mg/mL-125mM) was prepared in anhydrous Dimethylsulfoxide (DMSO, Fluka) and 52 μLof the solution was added to the Variant 1 solution. The solution wasincubated at room temperature for 45′. Then the solution was spunthrough a spin-column (Zeba spin-column 5 mL, Pierce #89890)equilibrated in phosphate buffer 20 mM pH 6. Isopropanol was added tothe solution to obtain a solution containing 35% isopropanol.

Example 6: Preparation of the Conjugate DSPE-PEG-SH

DSPE-PEG2000-SH (DSPE: distearoyl phosphatidyl-ethanolamine modifiedwith PEG2000) was prepared from DSPE-PEG2000-PDP (1,2Distearoyl-sn-glycero-3-phosphoethanolamine-N-[3-(2-pyridyldithio)propionate(polyethylene glycol)-2000] ammonium salt) according to example 10 ofWO2012/020030. The final solution of DSPE-PEG2000-SH was diluted withIsopropanol to obtain a solution containing 35% Isopropanol.

Example 7: Preparation of DSPE-PEG-SH/Variant 1A-SMCC Conjugate

1.7 mL of Variant 1A-SMCC (65 nmoles) solution obtained in example 5 wasadded to a solution of DSPE-PEG2000-SH (325 nmoles-5 equivalents)obtained in example 6. The solution was incubated for three hours atroom temperature with stirring (rotating wheel).

The solution was then purified by anion exchange chromatography with anANX Sepharose gel (GE Healthcare). The solution containing the purifiedVariant 1 conjugate was spun through a spin column (Zeba spin column 10mL, Pierce #89893) equilibrated in TRIS buffer 20 mM pH 7.5.

Example 8: Preparation of Microvesicles with the Conjugates of Example 7

10 mg of a mixture of DSPC (DSPC: Distearoylphosphatidylcholine) andPalmitic acid (80/20 molar ratio) were dissolved in cyclooctane (0.8 mL)at 70° C. Separately, the DSPE-PEG-SH/Variant 1-SMCC conjugate solutionprepared according to example 7 (28 nmoles-1.3 mL) was added to 8.7 mLof PEG4000 10% solution in distilled water. A solution of DPPE-PEG5000(DPPE: dipalmitoylphosphatidylethanolamine), (0.85 mg in 85 μL of water)was added to this aqueous phase.

The above prepared organic and aqueous solutions were admixed by using ahigh speed homogenizer (Polytron PT3000) to obtain an emulsion. Theresulting emulsion was heated under stirring at 60° C. for one hour thencooled to room temperature (about 22° C.).

The obtained emulsion was diluted twice with a solution of PEG4000 10%in distilled water and sampled in DINER vials (0.5 mL emulsion/vial).Vials were frozen at −50° C. for 1 hour (Lyobeta 35 freezedryer—TELSTAR), then freeze-dried at −20° C. and 0.2 mbar for 12 h. Thelyophilized product was then exposed to an atmosphere ofperfluoro-n-butane and nitrogen (35/65 v/v) mixture and the vials weresealed.

The product was dispersed in a volume of saline 150 mM (1 mL/vial) bygentle hand mixing.

Example 9: In Vitro Binding Activity of Targeted Microvesicles in aFlow-Chamber Setting

To test the effective binding, targeted microvesicles prepared asdescribed in WO2012/020030 (Example 6) and those prepared according tothe present invention (example 8) were injected in a flow chamber set upcomprising a coating of mouse Fc P-Selectin (catalog number 737-PS, R&DSystems, Minneapolis, Minn., USA) or human Fc P and E selectins (R&Dcatalog numbers 137-PS 50 and 724 ES 100) at 4 μg/mL. Microvesicles (atequivalent number of 80×10⁶/400 μL TBS++) were injected through the flowchamber (FCS2, Bioptech, USA) in a bolus fashion and their adhesion ontothe mouse P-selectin (or human P- or E-selectin) coating layer assessedover a period of 10 min at a flow rate of 1.0 mL/min (shear rate of 714s⁻¹) in the presence of 50% (v:v) human plasma (Stehelin & Cie A G) inTBS. A quantitative analysis of microvesicles accumulation was performedby counting the number of microvesicles adhering in the observed area at2 min intervals over the total 10 min infusion, using the imageprocessing program Analysis FIVE (SIS, Germany). After 10 min, fivepictures were taken randomly and the number of bound microvesicles wasmeasured and expressed as the number of bound bubbles (NBB) at 10 min.Each observed area was 183×137 μm, as measured with the aid of a stagemicrometer. Measurement was performed between the middle and the exit ofthe chamber.

Similarly, suspensions of targeted microvesicles prepared according toexample 8 (Variant 1A as targeting ligand) was injected in a flowchamber as described above, and their binding activity determinedaccording to the above procedure.

The experiment was repeated on coatings of human E-selectin and mouseP-selectin at the same concentration as above (4 μg/ml). The results areshown in Table 4.

TABLE 4 Number of Bound Microvesicles at 10 min (NBM 10 min) NBM 10 minHuman E Human P Preparation Mouse P selectin selectin selectinmicrobubble Fr-1 74.30 ± 4.27  54.1 ± 7.23  77.0 ± 4.83 microbubbleVariant 1A 73.60 ± 5.87 53.00 ± 4.37 65.40 ± 4.93

As inferable from the above results, the binding behavior of newlyprepared MB-PSGL-1 Variant 1A is similar to microbubble carrying Fr 1:they display firm binding without aggregation in plasma and bind bothhuman and mouse P-selectin as well as human E-selectin.

Example 10: In Vivo Experiments of Microvesicles with Fragment 1(Comparative) and Variant 1A

Microvesicles with Variant 1A prepared according to example 8 above andthose carrying Fragment 1 (Fr-1) prepared according to WO2012/020030,example 6, were compared in an inflammatory rat model. Inflammation wasinduced in the rat hind limb by injection of lipopolysaccharide (LPS,0.26:66 Sigma L-8274, 2.1 mg/kg). The effective binding of the targetedmicrovesicles was evaluated by ultrasound contrast imaging 24 h afterthe induction of the inflammatory process. Contrast enhanced ultrasoundimaging was performed usingLogiq E9 ultrasound scanner (General ElectricHealthcare, Fairfield, Conn., USA) equipped with the 9 L lineartransducer (transmit frequency, 4.0 MHz (Res); dynamic range, 48 dB;depth, 20 mm; Time-Gain Compensation (TGC), linear) operating incontrast mode. One image every second was recorded at low mechanicalindex (MI=0.06) during 30s and then one image every 15 seconds up tenminutes. Ten minutes after single dose injection, contrast enhancedsignal was acquired during 10 seconds at a frame rate of 4 Hz. Contrastenhanced images were recorded as Dicom files and analyzed using adedicated software developed in-house (VueBox, Bracco Suisse SA, Geneva,Switzerland). This software allows a quantitative analysis of theechographic signal after linearization of the log compressed videosequences at the pixel level and provides contrast echo-power amplitude(expressed as arbitrary unit, A.U.) within an area of interest (AOI).The fixed bubble imaging (FBI) algorithm integrated in the softwaredeveloped at Bracco (VueBox commercial kit) and helping to detect boundbubbles was applied on frames recorded at 10 minutes. The FBI processingrelies on a minimum intensity projection function applied on a subset ofimages which is dependent on the window length (40 frames). Theresulting images (FIG. 3) showed that microbubble carrying Variant 1Aare able to visualize inflammation in the inflamed paw of rat and thesignal observed is very similar to the one observed with microbubblescarrying Fr-1.

Example 11: Preparation of Fluorescent Liposomes with the Conjugates ofExample 7

Cholesterol (28.25 mg—Merck #3672) was dissolved in 1 mL of chloroform.DSPE-PEG2000 (13.9 mg—Genzyme #LP-R4-039) was dissolved in 1 mL ofchloroform. DiR(1,1′-Dioctadecyl-3,3,3′,3′-TetramethylindotricarbocyanineIodide—Molecular Probes #D12731) was dissolved in ethanol to obtain a 10mg/mL solution.

DSPC (79.7 mg-101 μmoles—Genzyme #LP-04-013) was weighed in a 100mL-round balloon and dissolved in 30 mL of chloroform/methanol mixture(2/1 v/v). Samples of the cholesterol solution (575 μL-42 μmoles), ofthe DSPEPEG2000 solution (290 μL-1.5 μmole) and of the DiR solution (100μL-1 μmole) were added to the DSPC solution. The obtained solution wasstirred at 65° C. for 10 min and the solvents were removed under reducedpressure to obtain a lipid blend. This blend was dried at 65° C. under20 mmHg then overnight at 25° C. under 0.2 mBar.

The dried lipid blend was redispersed in 10 mL of 20 mM Tris buffer (pH7.4) at 70° C. under stirring (rotavapor) for 20 min. The obtainedsuspension was then extruded at 70° C. several times on Nucleporefilters (1×1 μm, 1×0.6 μm and 4×0.4 μm). This extrusion step could beadapted to obtain various liposome sizes. The liposomal suspension wasthen cooled to room temperature and stored at 4° C. in the dark.

The incorporation of the variant conjugate was carried out by apostinsertion procedure. Briefly, 500 μL of liposome suspension wasmixed with 1 mL of Variant 1A conjugate solution prepared in example 7(22 nmoles) at room temperature for 16 hours in the dark. The obtainedliposome suspension was used without purification for in vivoexperiments.

Fr-1 liposomes were obtained using the same procedure described above,replacing Variant 1A conjugates by Fr-1 conjugates (prepared asdescribed in WO2012/020030, Example 6). The characteristics of the twoliposome suspensions were compared in Table 6.

Size and Zeta potential of liposomes were determined using a NanosizerZetaZSP (Malvern instruments). The density of ligand per liposome wasdetermined after liposomes washing (centrifugation 20000 g/30 min) bysialic acid determination (according example 3.3)

TABLE 5 Characteristics of control, Variant 1A and Fr-1 liposomes SizeZeta potential Ligand Liposomes (nm) (mV) molecules/liposome Withoutpostinsertion 268 −6.4 — Variant 1A conjugate 278 −39.1 780postinsertion Fr-1 conjugate postinsertion 291 −34.7 700

Example 12. Optical Imaging Experiments Using Liposomes with Fragment 1(Comparative) and Variant 1A in Mouse LPS Model

Liposomes carrying Variant 1A were compared to liposomes with Fragment 1in two groups of animals with hind limb inflammation. Inflammation wasinduced in the mouse hind limb by intramuscular injection oflipopolysaccharide (LPS, 0.26:B6 Sigma L-8274). Optical imaging wasperformed using the preclinical Fluobeam 700 system. The optical headwas placed above the animal so that its hind limbs were placed in thecenter of the field of view of the camera (distance between mouse andcamera 15 cm). Twenty-four hours after the induction of the inflammatoryprocess, the targeted liposomes were injected and the fluorescent signalwas followed over time (up to 24 h). The injection and the early phasewere recorded as a sequence with one image every 5 seconds during 16minutes (with fixed exposure time), followed by individual images at 20,30, 45 min, 1, 2, and 4 hours. The images were analyzed using Image Jsoftware. In all the capture frames, same area of interest (AOI) wasdrawn to outline the inflamed and contralateral paws. The meanfluorescence intensity per millisecond was calculated in the AOI of eachimage. Fluorescent images are presented in FIG. 4 and quantificationresults expressed as ratio (Inflamed paw divided by contralateral paw)are presented in Table 7. Fluorescent images recorded 2 hours afterVariant 1A-liposomes-DIR injection showed a higher signal in theinflamed paw compared to signal in the contralateral paw. In case ofanimal 3, the signal observed in the inflamed paw is low probably due toa low inflammation induced by LPS in this mouse. On the contrary, animal6 presents a high signal indicative of a high inflammation. Thecalculated inflamed paw/contralateral paw ratio is higher for theVariant 1A compared to the Fragment-1 (Fr-1) indicative of a goodspecificity of the agent.

TABLE 6 Inflamed paw to contralateral paw Ratio in LPS inflammatorymouse model, 2h after injection of either Variant A1-liposomes-DIR orFr-1-liposomes-DIR Inflamed/contralateral paw ratio (2h) Mouse N.Variant 1A Mouse N. Fr-1 1 13.2 7 4.3 2 23.0 8 6.0 3 3.9 9 3.5 4 18.0 104.1 5 6.6 11 4.7 6 12.8 12 5.3 Mean 12.9 4.7 S.D. 5.4 7.9

Example 13. Optimization of the Purification Conditions by HAChromatography (Negative or Positive)

Purification by AE/HI and HA (Negative)

600 mL of Conditioned Medium was filtered on 0.22 μm membrane and loadedonto AEX column (Capto Q™, GE, 2.6×7 cm, 37 mL) equilibrated with 20 mMTRIS pH 7.5. The bound proteins were eluted with 2 step elution at 30%and 100% of 20 mM TRIS, 1 M NaCl, pH 7.5. The target protein was elutedin the 100% fraction. The column was cleaned with 1 M NaOH, and storedat 4° C. in 20%. EtOH.

Conductivity of the conditioned medium was below 10 mS/cm.

Solid NaCl was added to the pool from the 100% elution step of the AEXpurification to a final concentration of 4 M. The sample was divided intwo parts in order not to overload the column. Then it was loaded on ahydrophobic interaction chromatographic column (Phenyl Sepharose™, GE,1.6×9 cm, 18 mL volume) previously equilibrated with 20 mM TRIS, 4 MNaCl, pH 7.5. The bound proteins were eluted with 2 steps at 50% and100% of 20 mM TRIS pH 7.5. The target protein was eluted in the 50%fraction.

After the second run, the column was cleaned with 0.2 M NaOH and storedat 4° C. in 20% EtOH.

The pools from the first elution step in the two HIC runs were combinedand the phosphate/CaCl₂ concentrations were adjusted to 10 and 0.3 mM,respectively, by addition of 500 mM phosphate pH 6.8 and 1 M CaCl₂. Thepool was then diafiltered against 10 mM Phosphate, 0.3 mM CaCl₂, pH 6.8in an Amicon™ ultrafiltration stirred cell (Merck, assembled withmembrane YM10, with 10 kDa nominal molecular weight cut off). Then, thediafiltered pool was loaded onto a Hydroxyapatite column (BioRad, 2.2×5cm, 19 mL volume) previously equilibrated with 10 mM Phosphate, 0.3 mMCaCl₂, pH 6.8. The PSGL Variant 1A was eluted in the FT fraction(negative chromatography).

The FT fraction was concentrated with Amicon™ Centrifugal Filter Unit,according to manufacturer's instructions. The purified protein wasfrozen at −40° C. The final concentration was 0.89 mg/mL for a totalyield of 38.7 mg (73%) and a purity of 99.7% (FIG. 5).

Residual DNA and protein contaminants were measured after eachchromatographic step, by a DNA quantitation assay (DNA Quantitation Kit,Fluorescence Assay, Sigma, detection limit 2 mg/L) and RP-HPLC (purityvs other proteins) respectively. Values are summarized in the followingtable:

TABLE 7 Purity and residual DNA content after 3-steps chromatographyPSGL Variant 1A Purification Step Purity by RP-HPLC Residual DNA contentAnion exchange (AE) <58% 97% Hydrophobic 72.6%  2% Interaction (HI)Hydroxyapatite (HA) 99.3% Below the detection limit

Purification by AE/HI and HA (positive)

1000 mL of Conditioned Medium was filtered on 0.22 μm membrane andloaded onto AE column (Capto Q™, GE, 2.6×7 cm, 37 mL) equilibrated with20 mM TRIS pH 7.5. The bound proteins were eluted with 2 step elution at30% and 100% of 20 mM TRIS, 1 M NaCl, pH 7.5. The target protein waseluted in the 100% fraction. The column was cleaned with 1 M NaOH, andstored at 4° C. in 20% EtOH.

Solid NaCl was added to the pool from the 100% elution step of the AEpurification to a final concentration of 4 M. The sample was divided intwo parts in order not to overload the column. Then it was loaded on ahydrophobic interaction chromatographic column (Phenyl Sepharose™, GE,1.6×9 cm, 18 mL volume) previously equilibrated with 20 mM TRIS, 4 MNaCl, pH 7.5. The bound proteins were eluted with 2 steps at 50% and100% of 20 mM TRIS pH 7.5. The target protein was eluted in the 50%fraction.

After the third run, the column was cleaned with 0.2 M NaOH and storedat 4° C. in 20% EtOH.

The pools from the first elution step of each HIC runs were combined anddiluted 4-fold with water. Then, the diluted pool was loaded onto aHydroxyapatite column (BioRad, 2.2×5 cm, 19 mL volume) previouslyequilibrated with 5 mM Phosphate, 1 mM MgCl₂, pH 6.8. The bound proteinswere eluted with a gradient from 0-12.5% of 500 mM phosphate buffer. ThePSGL Variant 1A was eluted as the first peak.

The fractions containing the target protein were concentrated withAmicon Centrifugal Filter Unit (Ultracel-10 membrane, 10 kDa MWCO),according to the manufacturer's instructions.

The purified protein was frozen at −40° C. The final concentration was1.09 mg/mL for a total yield of 25 mg, corresponding to about 70% of thetotal target protein content and a purity of 98.7%.

1. A recombinant chimeric P-Selectin Glycoprotein Ligand-1 (PSGL-1)protein comprising at least: a selectin Binding domain comprising atleast aa 5-16 of SEQ ID NO:11 (mature PSGL-1 sequence), leucine zipperdomain comprising an amino acid sequence at least 90% homologous oridentical to aa 187-208 of SEQ ID NO:12 (Neural Retina-specific LeucineZipper) and a disulfide bonds promoting region.
 2. The recombinantchimeric PSGL-1 protein according to claim 1 wherein the selectinBinding domain comprises at least an 1-47 of SEQ ID NO:11 (PSGL-1sequence).
 3. The recombinant chimeric PSGL-1 protein according to claim1 wherein said leucine Zipper comprises an amino acid sequence at least90% homologous or identical to aa 181-215 of SEQ ID NO:12.
 4. Therecombinant chimeric PSGL-1 protein according to claim 1 wherein saiddisulfide bonds promoting region comprises an amino acid sequencedefined by the following general formula:(X₁)n-C(X₂)m-(X₃) wherein: X₁, X₂ represents any amino acid or aminoacid sequence with the exclusion of cysteine (Cys), C is Cys X₃ is anyamino acid and n, m are integer numbers comprised from 1-6.
 5. Therecombinant chimeric PSGL-1 protein according to claim 4) wherein: X₁comprises a Proline, Histidine or Threonine; n is at most 5 and X₂comprises at least one Proline
 6. The recombinant chimeric PSGL-1protein according to claim 5) wherein: X₂ is Pro-Pro; X₃ comprises aCysteine and at least a Proline.
 7. The recombinant chimeric PSGL-1protein according to claim 6) wherein said disulfide bonds promotingregion is a IgG1 Hinge region (SEQ ID NO:20).
 8. The recombinantchimeric PSGL-L protein according to claim 1 further comprising apoly-glycine spacer comprising at least a lysine (Lys or K) or acysteine (Cys or C).
 9. The recombinant chimeric PSGL-I proteinaccording to claim 8) wherein said spacer is SEQ ID NO:17.
 10. A dimericprotein comprising two recombinant chimeric PSGL-1 proteins according toclaim 1 covalently linked to each other by at least a disulfide bond.11. (canceled)
 12. The recombinant chimeric PSGL-1 protein according toclaim 1 further comprising a signal peptide sequence suitable forsecretion and for being cleaved off before secretion.
 13. Therecombinant chimeric PSGL-1 protein according to claim 12 wherein saidsignal peptide is selected from the group consisting of: SEQ ID NO:18and SEQ ID NOs 21-34.
 14. (canceled)
 15. A DNA sequence encoding for therecombinant chimeric protein according to claim 1 comprising a selectinBinding domain comprising at least as 5-16 of SEQ ID NO:11 (maturePSGL-1 sequence), a leucine zipper domain comprising an amino acidsequence at least 90% homologous or identical to aa 187-208 of SEQ IDNO:12 (Neural Retina-specific Leucine Zipper) and a disulfide bondspromoting region.
 16. The DNA sequence according to claim 15) whereinsaid disulfide bonds promoting region comprises an amino acid sequencedefined by the following general formula:(X₁)n-C(X₂)m-(X₃) wherein: X₁, X₂ represents any amino acid or aminoacid sequence with the exclusion of cysteine (Cys), C is Cys X₃ is anyamino acid and n, m are integer numbers comprised from 1-6.
 17. Aneukaryotic expression vector comprising the DNA sequence according toclaim
 15. 18. The vector according to claim 17) further comprising SEQID NO:13, SEQ ID NO:15, or both encoding respectively for theglycosylating enzymes beta 1,6 N-acetylglucosaminyltransferase (C2GnT)and fucosyl-transferase VII (FTVII).
 19. A mammalian cell transformedwith the DNA or the vector according to claim
 15. 20. A mammalian celltransformed with the DNA vector according to claim 17 and with aneukaryotic expression vector comprising the nucleotide sequence encodingfor the glycosylation enzymes C2GnT and FTVII.
 21. The mammalian cellaccording to claim 19, which is a stably transfected CHO cell. 22.(canceled)
 23. (canceled)
 24. A conjugate compound comprising therecombinant protein according to claim 1 and a diagnostic or therapeuticmoiety.
 25. The conjugate according to claim 24) wherein the diagnosticmoiety is selected from the group consisting of: a radiolabel, anenzyme, a fluorescent label a luminescent label, a metal chelatingcompound, a gas-filled lipid microvesicle and a combination thereof. 26.(canceled)
 27. The conjugate according to claim 25) wherein the lipid ofthe gas-filled microvesicle is a phospholipid.
 28. The conjugateaccording to claim 24) wherein the therapeutic moiety is selected fromthe group consisting of: cytokine, cytostatic agent, toxin,anti-inflammatory agent, immunomodulator, antiaggregant, corticosteroid,monoclonal antibody, growth factor and radiotherapic agents comprisingmetal chelating moieties to carry a radionuclide.
 29. (canceled)
 30. Apharmaceutical composition comprising the recombinant chimeric proteinaccording to claim
 1. 31. Process for preparing a recombinant protein,which comprises transforming a eukaryotic cell with the DNA sequence ofclaim 15, growing the cell in a culture medium to achieve a recombinantsystem stably expressing the chimeric protein, harvesting the culturemedium and purifying the recombinant protein from said culture medium.32. (canceled)
 33. A process for purifying the recombinant proteinaccording to claim 1 which comprises a hydroxyapatite chromatography.34. (canceled)
 35. A method for the diagnostic imaging of a pathologiccondition characterized by overexpression of a selectin, which comprisespre-administering the pharmaceutical composition according to claim 30)to a subject and recording an image by using an imaging method selectedfrom the group consisting of: ultrasound, magnetic resonance,optoacoustic, scintigraphy, Single Photon Emission Computed Tomography(SPECT), Positron Emission Tomography (PET), X-Ray, radiofrequencyacoustic and optical.
 36. The method according to claim 35) wherein thepathologic condition is selected from the group consisting of: AcuteCoronary Syndrome (ACS), Inflammatory Bowel Disease (IBD), Ulcerativecolitis, Crohn's disease, neo-angiogenesis associated with tumors,Rheumatoid Arthritis, Ischemia Reperfusion Injury and Graft Rejection.37. A pharmaceutical composition comprising the conjugate according toclaim
 24. 38. Process for preparing a recombinant protein, whichcomprises transforming a eukaryotic cell with the vector of claim 17,growing the cell in a culture medium to achieve a recombinant systemstably expressing the recombinant protein, harvesting the culture mediumand purifying the recombinant protein from said culture medium.
 39. Amethod for the diagnostic imaging of a pathologic conditioncharacterized by overexpression of a selectin, which comprisespre-administering the conjugate according to claim 24) to a subject andrecording an image by using an imaging method selected from the groupconsisting of: ultrasound, magnetic resonance, optoacoustic,scintigraphy, Single Photon Emission Computed Tomography (SPECT),Positron Emission Tomography (PET), X-Ray, radiofrequency acoustic andoptical.